Prerpints.org logo
Preprint
Review

Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain

This version is not peer-reviewed.

Submitted:

31 December 2022

Posted:

04 January 2023

You are already at the latest version

A peer-reviewed article of this preprint also exists.

Abstract
Migraine and neuropathic pain (NP) are evocative of painful, disabling, chronic conditions which exhibit resembling symptoms and thus considered to share a common etiology. Calcitonin gene-related peptide (CGRP) has gained credit as a target for migraine management; nevertheless, the efficacy and the applicability of CGRP modifiers warrant search for more effective therapeutic targets for pain management. This scoping review overviews human studies of common pathogenic factors in migraine and NP to explore potential novel therapeutic targets. CGRP causes inflammation in the meninges; monoclonal antibodies and inhibitors target CGRP. Gluta-mate-induced hyperexcitability and subsequent sensitization are closely linked to an alteration of the tryptophan (Trp)-kynurenine (KYN) metabolic system; the Trp-KYN system may serve as a potential target. Microglial overaction is observed in migraine and NP; modifying the microglial activity may be a possible approach. Cytokine-induced inflammation is a leading hypothesis of the pathogenesis of the conditions; alleviating neuroinflammation may complement a pain-relieving armamentarium. Transient receptor potential (TRP) ion channels evoke the release of several substances; TRP ion channels may potentially emerge as new targets. The endocannabinoid system plays a major role in the pain trafficking pathway; modification of the system may open a new path toward discovery of new analgesics. Here we highlight the mechanism of those common pathogenic factors to explore therapeutic targets for innovative pain management in migraine and NP.
Keywords: 
Subject: 
Medicine and Pharmacology  -   Neuroscience and Neurology

1. Introduction

Migraine and neuropathic pain (NP) are chronic pain syndromes with extensively studied pathogenesis. While their clinical manifestations strongly differ, their pathophysiology has common roots. Cause-based treatment of these two devastating, painful neurological diseases is still unsatisfactory. Migraine is one of the frequent primary headache disorders with typical clinical features like unilateral throbbing or pulsating, moderate to severe headache with concomitant symptoms such as nausea, vomiting, photophobia, phonophobia, osmophobia and allodynia. Its main subtypes are migraine without aura (M0) and with aura (MA). Episodic (EM) or chronic (CM) forms can be differentiated based on the number of migraine days per month [1].
NP is a chronic secondary pain condition caused by a lesion or disease in the central or peripheral somatosensory system [2,3,4]. It is characterized by burning and lancinating pain with abnormal sensation, such as paresthesia, dysesthesia, or allodynia. We underline the difference of characteristics of these two painful conditions as follows quality of the pain (throbbing in migraine and burning in NP), the associated symptoms of migraine (nausea/vomiting, photophobia and phonophobia) which are absent in NP, the action of triptans (very effective in migraine, ineffective in neuropathic pain), the effect of nonsteroidal anti-inflammatory drugs (effective in migraine, ineffective in pure neuropathic pain). These two different clinical entities meet via their common pathomechanisms, like hyperexcitability and sensitization, which involve neuropeptides (mainly calcitonin gene-related peptide, CGRP), the glutamatergic system and microglia activation, pro- and anti-inflammatory cytokines and transient receptor potential (TRP) ion channel alterations and involvement of the endocannabinoid system [5,6,7,8,9,10,11,12,13,14,15,16].
CGRP is a vasodilator neuropeptide that plays a crucial role in the pathomechanism of migraine. CGRP is well-documented in pain transmission in the somatosensory nervous system. The latest therapeutic innovation is based on human and fully humanized monoclonal antibodies (mAbs) targeting CGRP and CGRP receptors. Clinical trials in EM and CM patients revealed high efficacy and safety of these pharmacons [17]. Clinical data showed that anti-CGRP mAbs provide strongly efficacious preventive treatment for both EM and CM. In NP co-existing CM only one study showed decrease in Neuropathic Pain Scale scores [18]. The glutamate system is involved in the pain process of hyperexcitability and sensitization. Kynurenines (KYNs) play pivotal roles in this process, since kynurenic acid (KYNA) is one of the rare endogenous antagonists of excitatory glutamatergic N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. The function of the KYN pathway in migraine and NP, based on the available human data and clinical trials, are summarized in this review [7,19].
Microglia are part of neuron-microglia interactions. In migraineurs, altered levels of S100B, a sensitive marker of glial cell injury, have been demonstrated, which point to the role of microglia in hyperactivation of the trigeminovascular system. Microglia play a fundamental role in NP transmission and in the sensitization process in the nervous system [9,10,20]. There is evidence that cytokines have pathophysiological roles in pain genesis and transmission. The key pro-inflammatory cytokines are interleukin-1 (IL-1), IL-2, IL-6, IL-17, IL-18 (previously interferon gamma) and tumor necrosis factor alpha (TNF-alpha), while the anti-inflammatory ones are IL-4, IL-10, and IL-37. There are controversial results with cytokines in the field of migraine, while in NP both pro- and anti-inflammatory cytokines are of significant importance [15,21].
TRP channels are involved in pain mechanisms. Several clinical observations have indicated that different agents (e.g., herbs, food, environment) have the ability to influence migraine headaches via modulation of subclasses of TRP superfamilies (TRP-ankyrin 1 - TRPA-1; TRP-vanilloid 1 - TRPV-1; TRP-melastatin 8 - TRPM-8) [13,22]. Research targeting TRP led to the innovation of the high concentration (8%) capsaicin dermal patch for different types of NP, such as painful diabetic neuropathy (PDN), postherpetic neuralgia (PHN) and human immunodeficiency virus (HIV)-associated neuropathy [23]. Elements of the endocannabinoid system exert antinociceptive effects through the activation of cannabinoid receptors. Favorable preclinical results, which showed decreased trafficking of pain transmission, were clinically confirmed in migraine patients. In the field of NP, only a few clinical studies are available [24].
In this review we overview the human data relevant to pathomechanisms, clinical trials, and therapeutic considerations in migraine and NP.

2. Calcitonin Gene-Related Peptide Function in Migraine and Neuropathic Pain

2.1. Migraine

The first clinical data on the importance of the trigeminovascular system in the pathomechanism of migraine revealed that CGRP plasma concentration was elevated in the external jugular vein during a migraine attack (Table 1) [25]. Later, increased CGRP plasma levels were also observed in the cubital vein during the ictal period, as compared with the interictal period [26]. Experimental work on human trigeminal ganglia demonstrated the distribution of CGRP and CGRP receptors [27,28].
The trigeminovascular system forms a bridge between cerebral dura mater and the vasculature of the meninges, cortex and second-order nociceptive neurons of the trigemino-cevical complex (TCC) [29,30,31]. One putative mechanism for the activation of the trigeminovascular system suggests that the peripheral branch of the pseudounipolar neurons of the trigeminal ganglion is triggered by cortical spreading depression, affecting different brain areas, like frontal regions. Due to this process, CGRP released in the peripheral and central branches of trigeminal neurons, lead to vasodilation and neurogenic inflammation in the meninges and the activation of second-order sensory neurons in the TCC. Second-order neurons then activate the third-order neurons in the thalamus [17,32].
The clinical sign of this activation and hyperexcitability is allodynia, which is a painful response to an innoxious stimulus. Allodynia can have cephalic or extracephalic localization [33]. A double-blind cross-over clinical trial revealed that intravenous infusion of alpha-CGRP versus placebo caused delayed migraine-like headache in migraineurs [34]. This was the first clinical observation which clearly demonstrated that CGRP can induce migraine attacks, leading to the development of small molecule CGRP receptor antagonists, the gepants. The second generation gepants (orally administered ubrogepant, rimegepant, atogepant) and the third generation version (intranasal application vazogepant) are available for acute and/or prophylactic treatment of migraine [35,36,37].
A novel pharmacological innovation produced human and fully humanized mAbs against CGRP and CGRP receptors to prevent EM and CM. Eptinezumab, fremanezumab and galcanezumab selectively bind to CGRP itself as a ligand, while erenumab competitively and reversibly targets CGRP receptor components. All of the above mentioned mAbs are highly effective and safe in the prophylaxis of both EM and CM [5,17,38,39,40,41].

2.2. Neuropathic Pain

Human studies have found that nerve fibers in the spinal cord lamina I, III and V had CGRP-like immunoreactivity, and their receptors are widely distributed in the pain pathways of the nervous system [42,43]. Experimental data showed that CGRP can sensitize nociceptors and also can induce central sensitization [43]. Allodynia is a clinical feature of central sensitization and is one of the most common sensory abnormalities indicating NP. In spite of these preclinical findings, available clinical data in this area are very sparse.
In skin biopsy samples of PHN patients, increased CGRP levels were found in keratinocyte [44] (Table 1). Complex regional pain syndrome (CRPS) has two types, both occuring after trauma, and peripheral nerve injury exists only in CRPS type 2. The latest classification by the International Association for the Study of Pain (IASP) suggests that CRPS type 2 may be associated with neuropathic mechanisms [45]. Clinical studies have demonstrated increased CGRP serum levels in patients suffering from CRPS [46]. In painful neuroma patients, higher densities of CGRP-immunoreactive nerve fibers were observed in comparison to controls [47]. A retrospective clinical study validated the effectiveness of CGRP-targeting mAbs in CM patients who also suffered from NP. Interestingly, in these patients the anti-CGRP treatment significantly improved the Neuropathic Pain Scale scores. The limitation of this study is that it was open-label, not placebo-controlled trial and the numbers of the patients were very low [18]. Allodynia is the common clinical feature of both migraine and NP. Peripheral and central sensitization, allodynia and responsiveness to anti-CGRP mAbs point to the potential common role of CGRP both in migraine and NP.

3. Kynurenine Function in Migraine and Neuropathic Pain

3.1. Migraine

The KYN pathway is the metabolic pathway of tryptophan catabolism. The determinative tryptophan degradation product is L-KYN, which serves as a precursor for KYNA. KYNA is one of the rare endogenous antagonists of excitatory amino acid receptors. By affecting glutamate receptors, it has a role in pain processing and neurogenic inflammation [6-8, 48, 49], as well as in cognitive dysfunctions. The sites of central sensitization are the second-order neurons of the TCC. This sensitization is induced by the release of glutamate from C-fibers of the central branch of pseudounipolar trigeminal neurons. Calcium ion influx and opened calcium storage in the cells result in increased intracellular calcium ion levels, which activate protein kinase C and lead to the phosphorylation of NMDA receptors. This process results in increased glutamate sensitivity, which is the basis for the hyperexcitability of the neurons [6,50].
Related to the above-mentioned process, clinical studies were performed using different body fluids including plasma, serum, cerebrospinal fluid (CSF), and saliva. Higher plasma glutamic acid levels were observed both during attacks and pain-free periods in M0 and MA patients (Table 2) [51]. High levels of glutamic acid in platelets were detected in patients with MA compared to M0 patients and healthy controls. Furthermore, glutamic acid platelet concentrations were higher ictally in MA patients [52].
In EM M0 and MA patients, plasma levels of glutamic acid were lower during attacks, while CSF concentrations of glutamic acid were higher in migraineurs than in controls [53]. Interictally, in the saliva of M0 patients, elevated glutamic acid concentrations were reported [54]. High glutamate concentration in the CSF of CM patients compared to controls was also demonstrated [55].
Imaging studies in migraine patients attempted to find a link between the glutamatergic system and specific brain regions. Altered excitatory neurotransmitter distribution in the anterior cingulate cortex and insula of migraineurs was observed by magnetic resonance imaging spectroscopy (MRI) [56]. Meta-analysis of MRI spectroscopy data during pain-free periods in patients suffering from M0, MA or CM revealed increased glutamate concentrations in particular brain regions [57,58]. In M0 patients, during a resting state functional MRI, altered periaqueductal gray matter functional connectivity (as a brainstem migraine generator and a pain modulator) was detected and correlated with plasma tryptophan concentration, both of which were higher in migraineurs than controls [59,60,61].
A rare subtype of MA, familial hemiplegic migraine (FHM) can be divided into three subclasses: FHM1, FHM2 and FHM3. The following genetic mutations led to the alteration of the glutamate system: In the patients suffering from FHM1, CACNA1A (encoding the α1 subunit of neuronal Ca,2.1. Ca2+ channels) gene disruption results in glutamate release from presynaptic nerve terminals. In FHM2 patients, the ATP1A2 gene (encoding the α2 subunit of Na+/K+ ATPase pumps) is damaged and indirectly reduces uptake of glutamate from the synaptic cleft in astrocytes. In FHM3, the SCNA1 (encoding the pore-forming α1 subunit of neuronal NaV1.1 Na+ channels) gene lesion can reduce firing of inhibitory interneurons and can increase glutamate levels in the synaptic cleft [62,63,64,65]. By studying these rare subtypes of MA, the role of glutamate has become better known.
CM is a distinct subclass of migraine, which develops if the patient suffers from more than 15 headache days per month, of which at least 8 days are with M0 or MA, for three consecutive months [1]. In CM, which is a devastating form of migraine headache that greatly affects quality of life, altered KYN pathway metabolites and reduction in serum levels of KYNA have been observed [66].
In a well-designed clinical trial examining female M0 patients during headache-free periods, plasma concentrations of tryptophan metabolites (L-KYN, KYNA, anthranilic acid, picolinic acid, 5-hydroxy-indoleacetic acid) were significantly decreased. The diminished peripheral tryptophan catabolism during the interictal period might act as a trigger for the migraine attack [67]. The first in-human, phase 1, open-label, single ascending dose study of L-KYN administered via intravenous infusion in healthy volunteers revealed that L-KYN was safe and well-tolerated [68].

3.2. Neuropathic Pain

A clinical sign of central sensitization is the phenomenon of allodynia, which mirrors the activation of the glutamatergic system in NP [6,19,69]. Overactive glutamatergic transmission via NMDA receptors is the basis of central sensitization in NP. Blocking the allosteric glycine B co-agonist site on NMDA receptors leads to antagonism of the glutamate system. L-4-chlorokynurenine, a novel oral prodrug, is a potent and selective glycine B site inhibitor.
A cross-over randomized controlled trial (RCT) revealed that NGX426, an oral AMPA-kainate receptor antagonist, reduced capsaicin-induced pain and hyperalgesia in healthy volunteers [70]. A Phase 2 outpatient RCT examining LY545694 tosylate, a potent and selective ionotropic glutamate receptor antagonist, in PDN patients did not demonstrate a difference compared to the placebo [71]. A dose-escalation RCT demonstrated a consistent reduction of allodynia and mechanical and heat hyperalgesia in an intradermally capsaicin-induced pain model in healthy volunteers [72].
In CRPS patients, plasma levels of L-glutamate significantly increased, whereas L-trp significantly decreased when compared to controls. The L-KYN to L-trp (KYN/Trp) ratio exhibited a significant increase in patients. A significant correlation between overall pain and plasma levels of L-glutamate and the KYN/Trp ratio was detected. A correlation between the decrease in plasma L-tryptophan concentration and disease duration was also observed in CRPS patients (Table 2) [73].
An exploratory pilot study involving female patients with NP-like syndromes, such as temporomandibular disorders myalgia and fibromyalgia, showed associations between the KYN/Trp ratio and pain intensity. In temporomandibular disorders myalgia, a significant negative correlation between plasma tryptophan concentration and worst pain intensity, and a positive correlation between the KYN/Trp ratio and both worst and average pain intensity were observed. Women suffering from fibromyalgia exhibited significantly lower plasma tryptophan levels than controls [74].
In addition to neuropeptides, the pathomechanism of hyperexcitability and sensitization is an overactivated glutamate system, both in migraine and NP. Alteration of the KYN system has been reported in these two painful clinical conditions. Metabolites of the KYN pathway might have future therapeutic potential for migraine and NP.

4. Glial Function in Migraine and Neuropathic Pain

4.1. Migraine

The trigeminovascular system is the backbone of the most accepted hypothesis for migraine pathogenesis. The center of this system is the trigeminal ganglion, which involves pseudounipolar neurons and satellite glial cells. There are strong data that glial cells have a role in peripheral sensitization and neuroinflammation, which lead to migraine chronification and the development of autonomic symptoms during migraine attacks [75,76].
S100B is a calcium-binding protein in the cytoplasm of glial cells in the nervous system, and it is a sensitive marker for glial cell injury. Clinical studies used it as a biomarker for the detection of glial involvement in the pathomechanism in EM and CM patients, ictally and interictally. Unfortunately, the results are controversial. In a clinical study which was performed during and after migraine attacks (2-4 days), the serum concentration of S100B was elevated (Table 3) [77]. A trial of M0 patients revealed increased serum S100B levels in both ictal and interictal phases [20]. A cross-sectional prospective study of M0 and MA patients revealed that serum S100B levels were significantly lower than in controls, and the two study groups did not differ [78]. A pilot RCT in CM patients revealed that ibudilast (a potential glia inhibitor) treatment did not reduce the frequency of headache, but it was well-tolerated [79]. In a case-control trial, serum levels of S100B were analyzed in EM and CM patients, and the results showed no interictal S100B elevation [80]. In EM and CM patients, the serum level of S100B was significantly higher compared to controls, and there was no difference between the two patient groups [81].

4.2. Neuropathic Pain

In a case of peripheral nerve lesion (peripheral arm of neurons of the dorsal root ganglia), one of the main consequences was ATP release from the central terminals in the dorsal horn of the spinal cord. ATP acts on microglia via purinergic P2X4 receptors and results in the release of brain-derived neurotrophic factor from the activated glial cells. This trophic factor stimulates second-order neurons via the activation of tyrosine kinase B receptors. The result of this process is central sensitization of the second-order neurons leading to the development of allodynia as a main clinical sensory sign of NP. It also leads to overactivation of the third-order neurons in the thalamus [6,82,83,84,85,86,87]. Based on these findings, NP can be considered a gliopathy [88, 89].
An early PET study, using a sensitive in vivo marker of glial cell activation, demonstrated activated glial cells in the contralateral thalamus after limb amputation, which pointed to a long-term transsynaptic glial response in the central nervous system (CNS) following peripheral nerve injury (Table 3) [90]. A functional imaging technology using novelly synthesized glia-PET tracers emphasizes the importance of neuron-microglia interactions in the mechanism of NP [9].
Preclinical studies confirmed that opioids could activate microglia via the toll-like receptor 4 and the myeloid differentiation factor 2 receptor complex. The consequence was an activated mitogen-activated protein kinase (MAPK) system, which resulted in interleukin gene activation, leading to neuroinflammation [91,92].
Motor cortex stimulation is a potential therapeutic method for relief of NP. In a clinical study, epidural strips were implanted over the motor cortex in central post-stroke NP patients and one trigeminal nerve injury NP patient. A comparison of postoperative PET with preoperative scans demonstrated significant decreases in a tracer, [(11)C]diprenorphine, binding to opioid receptors in different brain areas. Binding changes in the anterior middle cingulate cortex and periaqueductal gray matter were significantly correlated with pain relief [93]. A brain imaging study (integrated PET/MRI) with the new generation ligand 11C-PBR28 of translocator protein (TSPO), as a marker of glial activation, demonstrated increased binding to the pain matrix in chronic low back pain patients [94]. Peripheral benzodiazepine receptor, 18 kDa TSPO, is upregulated in activated microglia. PET imaging studies using a specific tracer related to TSPO showed higher activation of the thalamus, anterior and posterior central gyri and paracentral lobule in pain patients versus controls [9].
The inhibition of the activated microglia in NP might be a novel therapeutic target. A CNS glial modulator, propentofylline, administered orally, failed to decrease pain in PHN patients in a proof-of-concept clinical trial (Protocol SLC022/201, EudraCT number 2008-002108-24). Activated p38 MAPK in spinal microglia was detected in peripheral nerve injury-associated NP [95]. A RCT in patients suffering from peripheral NP following nerve injury treated with p38 MAPK inhibitor (dilmapimod) revealed significantly decreased daily average pain scores [95]. An in vitro study revealed that human and rodent microglia responded differently to propentofylline (SLC022) [96]. Another p38 MAPK inhibitor, losmapimod, which was investigated in a RCT in patients with NP from lumbosacral radiculopathy, failed to decrease pain intensity [97].
In a prospective, open-label, pilot RCT in PDN patients, minocycline, a tetracycline antibiotic as a microglial inhibitor, significantly improved Visual Analog Scale scores [98]. In another clinical trial involving NP patients, minocycline failed to decrease pain intensity [99]. The neuron-microglia interaction is a rate-limiting step in sensitization, both in migraine and NP. The overactivated glial cells have potential effects in the trigeminal ganglia during the pain process in migraine, while they show activation in the dorsal horn of the spinal cord and in the thalamus in NP. However, the results regarding glial biomarkers, like S100B protein, are controversial in migraine. Modern functional imaging techniques are available to detect the presence of hyperactivated glia in the CNS in NP patients. Unfortunately, thus far, microglia inhibitors have failed to reduce pain intensity in these conditions.

5. Cytokine Function in Migraine and Neuropathic Pain

5.1. Migraine

In the late eighties and early nineties, clinical studies demonstrated that intravenously administered TNF produced headache in tumorous patients [100,101,102,103]. There is growing evidence that cytokines play a role in a genesis of migraine pain. They are released by neurons, microglia, astrocytes, macrophages, mast cells and T-cells. Human studies reflect that the pro-inflammatory cytokines are TNF-alpha, IL-1beta, IL-6 and IL-18 [15,76]. Given that, a balance of pro- and anti-inflammatory cytokines is important for neural functions. The pro-inflammatory cytokines may have a role in inducing nausea and headache during a migraine attack by increasing arachnoid acid production [15]. Several trials investigated the pro- and anti-inflammatory cytokines in plasma, saliva and CSF of migraineurs. In an early clinical study, there were no differences in plasma IL-1 and TNF during migraine attacks compared to headache-free periods in M0 and MA patients (Table 4) [105].
A clinical trial analyzed IL-1beta, IL-6 and TNF-alpha in 24-hour urine samples in female migraineurs, during menstrual and non-menstrual migraine attacks and headache-free periods and compared them with non-headache controls. Mean IL-6 levels in urine were higher in all three samples of migraineurs versus controls, while IL-1beta levels showed no difference. TNF-alpha values were very low in menstrual migraineurs compared to controls [105].
Another clinical trial failed to demonstrate differences in serum concentrations of TNF-alpha and IL-6 between M0 and MA patients compared to controls, however the soluble receptor TNF-RI tended to be lower [106]. A clinical study of migraine patients revealed that the plasma levels of TNF-alpha, IL-1beta and IL-10, as an anti-inflammatory cytokine, were significantly higher ictally versus interictally [107]. TNF-alpha levels in internal jugular blood of M0 patients was elevated during ictal periods [108]. A clinical trial demonstrated that IL-10 serum levels were higher during migraine attacks versus the intervallum period and healthy controls. Furthermore, IL-6 serum concentrations were increased in migraineurs compared to controls [109]. A pilot study of EM patients demonstrated no significant difference in the serum levels of TNF-alpha during the attacks or headache-free periods [110]. A case-control study investigating newly diagnosed migraine patients revealed significantly higher serum IL-1beta and IL-6 concentrations, while IL-10 serum levels were lower compared to healthy controls [111]. A clinical study investigating M0 and MA patients in both attack and pain-free periods revealed that serum levels of IL-6 were significantly higher in migraine patients during attacks compared to controls [112].
A prospective, case-control RCT in migraineurs concluded that the serum concentrations of TNFalpha, IL-1beta and IL-6 were significantly higher during the migraine attack compared to controls [113]. In the MOXY study, which studied female migraineurs responsive to adjunctive cervical non-invasive vagus nerve stimulation, interictal saliva ELISA assays of IL-1beta showed significantly elevated values both pre- and post-VNS procedure compared to healthy controls [114]. The evaluation of the inflammatory state in migraineurs versus healthy controls in a case-control study demonstrated that the serum levels of TNF-alpha and IL-6 were significantly increased in CM as opposed to EM patients and controls [115]. The SalHead longitudinal prospective cohort study, analyzing salivatory IL-6 and IL-1beta levels, observed non-significant differences at different time-points (headache-free period versus during headache versus one day after headache) between migraine patients and tension-type headache patients. Salivatory levels of IL-1beta showed the highest discriminative value between headache patients and healthy controls [116]. Investigation of serum IL-18 (previously interferon-gamma) levels in M0 and MA patients, ictally and interictally, revealed that they were higher in migraineurs than in the control group. IL-18 serum concentrations did not show differences ictally versus interictally [117].
An interesting study, analyzing the pro- and anti-inflammatory cytokine levels in the CSF, revealed that IL-1 receptor antagonist levels were elevated in M0 and MA patients during attacks compared to controls. There were significant differences in the CSF levels of certain cytokines (IL-1 receptor antagonist, monocyte chemoattractant protein-1 and transforming growth factor-beta1) in migraine and episodic tension-type headache compared to pain-free controls. The intrathecal pro-inflammatory monocyte chemoattractant protein-1 level was correlated with IL-10 anti-inflammatory cytokine in MA patients [118].
The analysis of genetic variations of cytokines provided useful data regarding the neurinflammation process of migraine. A genetic study showed significant differences in the TNF-alpha -308G/A and IL-1beta +3953C/T gene polymorphisms in migraineurs versus control subjects [119]. A meta-analysis from 2011, focusing on TNF-alpha 308G>A and TNFbeta 252A>G gene polymorphisms among migraine patients, concluded no overall association between the above-mentioned gene variants and migraine [120]. Another meta-analyis, published in 2014, revealed that TNF-beta 252A>G gene polymorphism was not associated with overall migraine risk [121]. A clinical study analyzing omega-3 fatty acids and nano-curcumin supplementation targeting TNF-alpha gene expression and serum concentrations in migraine patients demonstrated that the TNF-alpha messenger ribonucleic acid (mRNA) was significantly downregulated, and the serum level of TNF-alpha was decreased [122].
A RCT in EM patients revealed downregulated IL-6 mRNA and decreased IL-6 serum concentrations [123]. Investigation of the IL-6 coding gene in peripheral blood of M0 and MA patients demonstrated no significant differences in expression of IL-6 between total migraine patients and healthy controls. However, the expression of IL-6 was significantly higher in MA patients versus controls [124]. A clinical study investigating cytokine-coding gene expression in blood among M0 and MA patients revealed that the expression of IL-4, tumor growth factor-beta (TGF-beta) and TNF-alpha was increased in patients compared to controls, but there was no difference in expression levels of IL-1beta, IL-17 and IL-2. Expression of IL-18 was also higher in migraineurs (lower in women than in men) compared to healthy controls [125]. A genetic study focusing on the TNF-alpha gene polymorphisms (rs1800629 and rs1799724) among Jordanian migraineurs showed significant associations with migraine occurrence [126]. For future therapeutic innovations in migraine, IL-37, as an anti-inflammatory cytokine, may be a crucial player. IL-37, as a natural inhibitor of immune response and inflammation, can diminish pro-inflammatory IL-1 activation and upregulate the anti-inflammatory IL-10 [15]. A recent meta-analysis of peripheral inflammatory cytokines in migraine concluded that IL-1beta, IL-6 and TNF-alpha serum levels were higher when compared to healthy controls, while IL-2 and IL-10 (an anti-inflammatory cytokine) did not show significant differences [127].

5.2. Neuropathic Pain

There is increasing evidence that cytokine expression is a contributor to NP [128]. In the development of NP, TNF-alpha, IL-1, and IL-6 may have fundamental roles in inflammation [129]. Cytokine action sites involve peripheral nerve endings, dorsal root ganglia, the synaptic junction in the dorsal horn of the spinal cord and distinct regions of the brain (like the hippocampus, locus coeruleus, red nucleus) [129,130,131].
A clinical investigation of nerve biopsies in painful and non-painful neuropathic patients revealed upregulated TNF-alpha expression in human Schwann cells in the painful group (Table 4) [132]. A clinical study focusing on mRNA expression and plasma protein levels of cytokines in patients who have painful versus painless neuropathies demonstrated that both measured parameters of pro-inflammatory cytokines (IL-2 and TNF-alpha) were increased in the painful patient group, while IL-4 and IL-10, as anti-inflammatory cytokines, were lower in this group compared to painless patients [133]. A clinical investigation of PDN and painless diabetic neuropathic patients indicated increased TNF-alpha serum levels in the neuropathic group compared to non-neuropathic and healthy groups [134].
A prospective genetic study analyzing local (skin) and systemic (plasma) cytokine gene expression in patients suffering small fiber sensory neuropathy revealed that local gene expression of IL-6 and IL-8 (chemokine) were significantly increased (5-fold), while only mildly elevated gene expression of IL-2 and IL-10 was detected in the plasma (2-fold) [128].
A cross-sectional study revealed that plasma TNF-alpha levels and immunoreactivity for TNF-alpha were higher in patients with severe pain, based on VAS in PDN patients, compared with controls [135]. A prospective RCT in patients suffering low back and leg pain, caused by lumbar disc herniation and lumbar spinal canal stenosis, who were treated with epidurally administered etanercept (an anti-TNF mAb) versus dexamethasone, demonstrated that etanercept significantly decreased both leg and low back pain [136]. The same clinician group published the results of a clinical trial using epidurally applied tocilizumab onto the spinal nerve as an anti-IL-6 receptor antibody for patients with low back and radicular leg pain caused by lumbar spinal stenosis. They concluded that infiltration of tocilizumab was more effective than dexamethasone in these patient groups [137]. A double-blind, placebo-controlled trial evaluating the analgesic effect of losmapimod (a p38 alpha/beta inhibitor) in patients with NP after peripheral nerve injury revealed that losmapimod statistically did not differ from analgesic response to the placebo [138].
A prospective study of patients with painful or painless peripheral neuropathy demonstrated that painful neuropathies are associated with increased pro-inflammatory IL-6 and anti-inflammatory IL-10 gene expression in the sural nerve [139].
A clinical trial including patients with painful distal sensorimotor polyneuropathy (DSPN) from the German KORA F4 survey found positive associations between serum concentrations of IL-6 and painful DSPN, whereas no associations were observed for IL-18, TNF-alpha and IL-1 receptor antagonists [140]. A parallel-group RCT, in patients suffering central NP associated with spinal cord injury, revealed that in the anti-inflammatory diet treatment group the serum levels of pro-inflammatory cytokines, such as interferon-gamma (later named IL-18), IL-1beta and IL-6 were decreased [141]. A cross-sectional study assessing different serum biomarkers, including cytokines (oncostatin, TNFSF10, TNFSG12, TNFSF14), in patients with diabetic polyneuropathy did not find differences in biomarker levels between painful and painless DSPN patients [142].
A genetic trial focused on patients with and without NP after peripheral nerve lesion revealed that in white blood cells the gene expression of TNF-alpha was higher in patients with pain compared to those without. IL-1beta gene expression was higher in painful patients compared to controls. IL-10 showed lower gene expression than in the control group, and IL-4 gene expression was not different between the control and painless patients [16].
A pilot RCT in patients with peripheral NP due to PHN examined mRNA expression of IL-6 in two study groups. In group 1, PHN-related NP patients received pregabalin monotherapy alone, while Group 2 patients were treated with a combination of pregabalin together with cognitive behavioral therapy. The results showed that patients in Group 2 had significant downregulation of IL-6 mRNA expression [143].
A recent meta-analysis focused on the association of pro-inflammatory (TNF-alpha, IL-2, IL-6, IL-18) and anti-inflammatory (IL-10) cytokines, as systemic inflammatory biomarkers in painful and painless diabetic neuropathy. It concluded that serum levels of pro-inflammatory markers were increased, while anti-inflammatory ones were lower in painful compared to painless diabetic polyneuropathy [21].
In migraine, whether in ictal or interictal phases, the data regarding cytokines are controversial, but pro-inflammatory cytokines tend to be elevated in human clinical trials. In the NP patients, the levels of pro-inflammatory cytokines also showed elevation compared to controls in the majority of the clinical studies.

6. Transient Ion Channel Function in Migraine and Neuropathic Pain

6.1. Migraine

TRP ion channels are non-selective cation channels and can be divided into six subfamilies: TRPV (vanilloid), TRPA (ankyrin), TRPM (melastatin), TRPC (canonical), TRPP (polycystin) and TRPML (mucolipin) [144]. Preclinical studies have concluded the putative role of TRPs in migraine. The activation of TRPs (TRPA-1, TRPV-1) in the TCC results in CGRP and substance P release and depletion from the central branch of trigeminal nerve endings. The consequences are overexcited, second-order, pain-processing neurons in the TCC, which lead to central sensitization. The peripheral parts of the trigeminal nerve terminals, projecting into cerebral dura mater and the vasculature of the meninges, contain TRPs. The activation of TRPs leads to CGRP release, which can act on its receptors on the smooth muscle cells of blood vessels, resulting in strong vasodilation [144,145].
Capsaicin, as a potent and highly selective TRPV-1 receptor agonist, is a chemical compound isolated from chili pepper. A RCT using intranasal civamide (a synthetic stereoisomer of capsaicin) for M0 and MA patients during headache attack revealed decreased pain severity at 2 hours post-dose in 55.6% of patients, and 22.2% of patients were pain-free [146]. A double-blind study in CM patients demonstrated that repeated intranasal capsaicin application had favorable effects [147]. A single-blind, placebo-controlled, cross-over study in small numbers of M0 patients, who were treated with topical capsaicin (0.1%) jelly, led to relief of arterial pain by at least 50% [148].
TRPM-8, a non-selective cation channel, can be activated by cold temperature and menthol. A triple-blind RCT revealed that a 10% menthol solution applied to the forehead and temporal skin areas was significantly superior to the placebo at 2-hour pain freedom [149].
Extensive preclinical studies focusing on TRP ion channels concluded that TRPA-1 and TRPV-1 could play crucial roles in the activation of several substances (as migraine triggers) that evoke migraine pain. Odors (cigarette smoke, formalin, Umbellularia californica – ‘headache tree’) are triggering and worsening factors for migraine attack via TRPA-1 receptor agonism. Other agents, such as Tanacetum parthenium (feverfew) and Angelica sinensis (dong quai, female ginseng), as desensitizing TRPA-1 receptor agonists, are migraine preemptive factors. A well-known migraine trigger factor, glyceryl trinitrate (nitroglycerine-NTG) as a nitric oxide donor, is also a TRPA-1 receptor agonist [22]. Long-term recognized migraine trigger factors are alcohol-containing drinks (ethanol), which are TRPV-1 receptor agonists. Capsaicin, as a pungent ingredient of paprika (Capsicum), is a desensitizing agonist of the TRPV-1 receptor [22].
An unusual clinical study, examining scalp arteries (superficial temporal and occipital arteries) of CM patients, demonstrated significantly increased TRPV-1-like immunoreactive nerve fiber density in the wall of arteries of CM patients versus control (Table 5) [150].
A recent pilot study, searching for predictors of migraine chronification, investigated the 1911A>G single nucleotide polymorphism (SNP) in the TRPV-1 gene in patients with EM and CM compared to healthy subjects. The results showed that genotype frequency distribution in EM was comparable with controls, while it differed significantly in CM patients [151]. Another genetic study, among Spanish migraine patients, demonstrated association with migraine and SNPs of the TRPV-1 and TRPV-3 receptor genes [13,152]. The above discussed clinical data led to the design of early phase clinical trials targeting thermoTRP channels for migraine treatment, such as an oral TRPV-1 receptor antagonist (NCT00269022), a TRPM-8 receptor agonist (topical menthol 6%) (NCT01687101) and a TRPM-8 receptor antagonist (oral AMG 333) (NCT01953341) [153]. Final results are not yet available.

6.2. Neuropathic Pain

Nociceptors are special afferent sensory neurons which convey thermal, mechanical and chemical stimuli. The members of the TRP family are densely expressed on nociceptors. Therefore, they have fundamental roles in nociception and NP transmission [154,155,156,157]. A high concentration (8%) capsaicin patch reversibly de-functionalizes nociceptive nerve terminals [14,158]. Based on the latest Cochrane Database, the 8% capsaicin patch is effective, well-tolerated and safe for treatment of PHN, HIV-neuropathy and PDN (Table 5) [23]. Clinical trials revealed that 8% capsaicin patch significantly reduced the average pain intensity in chronic postsurgical NP [159]. A retrospective observational study, collecting different types of peripheral NP patients (PHN, chronic postsurgical NP, post-traumatic NP, PDN, HIV-associated NP, painful radiculopathy, trigeminal neuralgia), demonstrated a reduction in pain intensity and pain area after 8% capsaicin patch application [160]. The 8% capsaicin patch can provide pain relief for up to 3 months or longer after a single 30-60 min application in chemotherapy-induced NP [161].
Early phase clinical studies targeting thermoTRP channels for NP treatment, including an intranasal TRPV-1 receptor agonist in PHN (NCT01886313), a subcutaneous TRPV-1 receptor inhibitor (parentide) in non-specified NPs (EP002846-21), an oral TRPV-3 receptor antagonist for non-specified NPs (NCT01463397) and a TRPM-8 receptor agonist (topical menthol 7%) for chemotherapy-induced peripheral neuropathy (NCT0185567) are under way [153]. Published data are not yet available.
Capsaicin, as a potent TRPV-1 receptor agonist, can decrease the intensity of pain either in migraine or NP via modulation of the release of pain-related neuropeptides from nociceptors. In migraine, several agents targeting TRPA-1 and TRPV-1 receptors can trigger or preempt the headache attacks. The high concentration (8%) capsaicin patch is strongly recommended for treatment of peripheral NPs such as PDN, PHN and HIV-neuropathy. Early phase clinical trials are ongoing both in migraine and NPs.

7. Endocannabinoid Function in Migraine and Neuropathic Pain in Humans

7.1. Migraine

Endocannabinoids are endogenous cannabis-like substances. Chemically, they are characterized as small molecules and they are derived from arachidonic acid. As neurotransmitters, the endocannabinoids are part of the biological endocannabinoid system and they act on cannabinoid receptors (cannabinoid receptor (CBR) type 1 and CBR type 2-CBR-2). Their main endogenous ligands are anandamide (N-Arachidonoylethanolamine) and 2-arachidonoylglycerol (2-AG). Moreover, the system involves enzymes that regulate the synthesis and degradation of the ligands. CBR-1 is located in the nervous system – mainly in the brain, while CBR-2 is found in immune system [24].
In the endocannabinoid system, one of the main catabolic enzymes is fatty acid amide hydrolase (FAAH), which catabolizes fatty acid ethanolamides, such as anandamide. Other enzymes of this system include monoacylglycerol lipase (MAGL), diacylglycerol lipase alpha, diacylglycerol lipase beta and alpha/beta hydrolase domain 6. Fatty acid ethanolamides, together with 2-AG, are the main endocannabinoid signaling lipids interacting with CBR-1 and CBR-2 [24,162]. The endocannabinoid system seems to be dysfunctional and dysregulated in migraine. It interacts with migraine-related pathways, like the serotonin system (5-HT1A, 5-HT2A receptors), the migraine generator (periaqueductal grey matter), meningeal vessel dilatation and activation of the TCC [163,164].
In a clinical trial, the activity of FAAH and the specific anandamide membrane transporter (AMT) was measured in platelets taken from the peripheral blood of M0 patients and healthy controls. The results showed significant sex differences in the activity of FAAH and AMT in both study groups, namely an increase in the activity of FAAH and AMT was found only in female, but not male, M0 patients (Table 6) [165]. A study focused on the examination of anandamide, palmitoylethanolamide (PEA) and 2-AG concentrations in the CSF of patients with CM compared to control subjects. The results showed that CSF concentrations of anandamide were significantly lower, while those of PEA were significantly higher in CM patients versus the non-migraineur control group. 2-AG concentrations were below detection level in both patient and control groups [166].
A comparative clinical trial demonstrated that the levels of AMT and FAAH were significantly reduced in platelets of CM patients compared to EM patients and the control group, and this was observed for both sexes [167]. A clinical study investigating the levels of anandamide, 2-AG and serotonin in platelets of CM patients and healthy controls found that anandamide and 2-AG platelet levels were significantly lower in CM patients versus controls. Furthermore, serotonin levels in platelets were also strongly reduced in the CM group and were correlated with 2-AG levels [168]. An observational, cross-sectional study comparing the binding of CBR-1, as detected by positron emission tomography (PET), among female migraine patients demonstrated a global increase, which was most pronounced in the anterior cingulate, mesial temporal, prefrontal, and superior frontal cortices of the brain in migraineurs compared to healthy controls [169].
A clinical trial was designed for migraineurs with medication-overuse headache, before and after withdrawal treatment. The results demonstrated a marked facilitation in spinal cord pain processing (increased temporal summation threshold of the nociceptive withdrawal reflex and reduction in related pain sensation) before withdrawal treatment when compared with controls. The acute significant reduction of FAAH activity in platelets was coupled with a reduction in the facilitation of pain processing after versus before withdrawal treatment [170]. A clinical study concluded that the plasma levels of anandamide and related N-acylethanolamines and linoleic acid-derived oxylipins did not show any differences between M0 versus MA patients and migraine versus healthy controls [171].
Results from a genetic study demonstrated a significant haplotypic effect of CNR1 (the gene of CBR-1) on headache with migraine symptoms (e.g., nausea, photophobia, disability) only when using extreme trait combinations (0 symptom versus 3 symptoms) [172]. Later, the same research group reported that variants in the CNR1 gene predisposed to headache with nausea in the presence of life stress. None of the SNPs showed primary genetic effects on possible migraine [173]. A RCT testing the effects of a 12-week aerobic exercise plan on plasma anandamide concentration and its relationship with clinical and cardiorespiratory outcomes in EM patients revealed plasma anandamide level reduction both in migraine and control exercise groups. Significant correlations were found between the reduction in abortive medication used and cardiorespiratory fitness and reduced anandamide plasma levels [174].
A recent pilot study in EM and CM with medication overuse headache patients demonstrated higher CBR-1 and CBR-2 gene and protein expression in peripheral blood mononuclear cells compared to controls. FAAH gene expression was lower in migraine groups compared to controls. Gene expression of MAGL was significantly higher in migraineurs [175]. In a clinical trial of EM patients and healthy controls, plasma anandamide and PEA, an anandamide activity enhancer, levels, and spinal sensitization were evaluated in a validated human model of migraine based on systemic NTG administration. After NTG administration, anandamide plasma levels were increased in both groups, while increased PEA plasma levels were detected only in the EM group [176].

7.2. Neuropathic Pain

Endocannabinoids exert effects on a wide range of biological cell functions, like exocytosis, proliferation, differentiation, and control of pain transmission via inhibiting the ascending stimulatory and activating the descending inhibitory pain pathways [177,178]. An early clinical study of patients suffering painful carpal tunnel syndrome demonstrated that treatment with PEA (daily administered 600 mg or 1200 mg for 30 days) significantly reduced median nerve latency time during nerve conduction tests [179]. In a later RCT, ultramicronized PEA treatment (administered sublingually) was investigated in patients with spinal cord injury-associated NP. The results showed no difference in mean pain intensity between ultramicronized PEA and the placebo treatment (Table 6) [180]. Based on promising preclinical data with FAAH and MAGL, clinical trials with MAGL inhibitors are ongoing. A randomized, placebo-controlled, optimized titration study with a MAGL inhibitor (ABX-1431) in PDN patients (NCT03447756) and a double-blind, placebo-controlled, cross-over trial in central (multiple sclerosis-associated) NP patients (NCT03138421) are being conducted. In both clinical trials, favorable safety profiles were observed. Detailed results related to efficacy are not yet available [24]. The importance of the endocannabinoid system in pain modulation has been known since the early 1990s. Based on clinical data of the ligands and enzymes in this system, a correlation has been shown with migraine. Only limited clinical data on how compounds of this system affect NP are available. In the future, CBR antagonists and FAAH and MAGL enzyme inhibitors might be promising therapeutic targets in treatment of both migraine and NP.

8. Conclusion

In this review we have summarized the available human clinical data and novel therapeutic approaches which overlap between migraine and NP, focusing on CGRP, KYNs, microglia, cytokines, TRP ion channels and endocannabinoids. Potential common factors in the pathomechanisms of migraine and NP are hyperexcitability and peripheral and central sensitization, which result in allodynia as a common clinical symptom of both painful disorders. One of the fundamental players of this process is CGRP. There are data from clinical trials indicating that CGRP-targeting mAbs treatment reduces pain intensity in both migraine and NP. Another participant in this process is an overactivated glutamate system. Altered metabolites in the KYN pathway have been observed both in migraine and NP, thus KYNs might offer valuable therapeutic targets for both entities. Common anatomical sites of neuron-microglia interactions are the trigeminal and dorsal root ganglia, the dorsal horn of the spinal cord and the thalamus. There are available human data which show overactivated glial function in the above-mentioned pain-related regions, so the innovation of microglial inhibitors as therapeutic targets, both in migraine and NP, is needed in the near future.
The results of preclinical studies indicate significant roles of pro- and anti-inflammatory cytokines in the hypothesized inflammatory processes of migraine and NP. Despite controversial human data regarding migraines, in NP elevated pro-inflammatory cytokines levels have been detected. Distinct TRP ion channels have marked roles in the pathomechanisms of both migraine and NP. Results of the clinical research have led to therapeutic options for migraines, while evidence in several types of peripheral NP highly recommends them. The endocannabinoids show shared mechanisms for migraine and NP via trigeminovascular and pain transmission systems. Future therapeutic possibilities might include CBR antagonists and FAAH and MAGL modulators.
In this review, human data on potential common factors in migraine and NP were analyzed, which support the hypothesis that these painful disorders have shared pathomechanical backgrounds. In the near future all of the substances discussed above have the potential to serve as biomarkers and novel therapeutic targets in both migraine and NP.

Author Contributions

Conceptualization, J.T., D.S., A.C., and L.V.; writing—original draft preparation, J.T., D.S., and A.C.; writing—review and editing, M.T. and L.V.; visualization, Á.S.; supervision, L.V.; project administration, L.V.; funding acquisition, L.V. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by OTKA-138125-K, TUDFO/47138-1/2019-ITM, and ELKH-SZTE Eötvös Loránd Research Network and the University of Szeged.

Acknowledgments

We are grateful to Jennifer Tusz, a native English language speaker for the corrections (e-mail: jentusz@gmail.com).

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

2-AG 2-arachidonoylglycerol
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
AMT anandamide membrane transporter
CBR cannabinoid receptor
CGRP calcitonin gene-related peptide
CM chronic migraine
CNS central nervous system
CRPS complex regional pain syndrome
CSF cerebrospinal fluid
EM episodic migraine
FAAH fatty acid amide hydrolase
FHM familial hemiplegic migraine
HIV human immunodeficiency virus
IL interleukin
KYN Kynurenines
KYNA kynurenic acid
L-KYN L-kynurenine
M0 migraine without aura
MA migraine with aura
mAbs monoclonal antibodies
MAGL monoacylglycerol lipase
MAPK mitogen-activated protein kinase
mRNA messenger ribonucleic acid
nd no data available
NMDA glutamatergic N-methyl-D-aspartate
NP neuropathic pain
NTG nitroglycerine
PDN painful diabetic neuropathy
PEA palmitoylethanolamide
PET positron emission tomography
PHN postherpetic neuralgia
RCT randomized controlled trial
TCC trigemino-cevical complex
TNF-alpha tumor necrosis factor alpha
Trp tryptophan
TRP transient receptor potential
TRPA-1 transient receptor potential ankyrin 1
TRPM-8 transient receptor potential melastatin 8
TRPV-1 transient receptor potential vanilloid 1
TSPO translocator protein

References

  1. Headache Classification Committee of the International Headache Society (Ihs) the International Classification of Headache Disorders, 3rd Edition. Cephalalgia: an international journal of headache 2018, 38, 1–211. [CrossRef] [PubMed]
  2. Jensen TS, Baron R, Haanpaa M, Kalso E, Loeser JD, Rice ASC, et al. A New Definition of Neuropathic Pain. Pain 2011, 152, 2204–2205. [Google Scholar] [CrossRef] [PubMed]
  3. Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. Chronic Pain as a Symptom or a Disease: The Iasp Classification of Chronic Pain for the International Classification of Diseases (Icd-11). Pain 2019, 160, 19–27. [Google Scholar] [CrossRef] [PubMed]
  4. Scholz J, Finnerup NB, Attal N, Aziz Q, Baron R, Bennett MI, et al. The Iasp Classification of Chronic Pain for Icd-11: Chronic Neuropathic Pain. Pain 2019, 160, 53–59. [Google Scholar] [CrossRef] [PubMed]
  5. Tajti J, Szok D, Nyari A, Vecsei L. Cgrp and Cgrp-Receptor as Targets of Migraine Therapy: Brain Prize-2021. CNS & neurological disorders drug targets 2021. [CrossRef]
  6. Vecsei L, Majlath Z, Balog A, Tajti J. Drug Targets of Migraine and Neuropathy: Treatment of Hyperexcitability. CNS & neurological disorders drug targets 2015, 14, 664–676. [Google Scholar] [CrossRef] [PubMed]
  7. Vecsei L, Szalardy L, Fulop F, Toldi J. Kynurenines in the Cns: Recent Advances and New Questions. Nature reviews Drug discovery 2013, 12, 64–82. [Google Scholar] [CrossRef] [PubMed]
  8. Spekker E, Tanaka M, Szabo A, Vecsei L. Neurogenic Inflammation: The Participant in Migraine and Recent Advancements in Translational Research. Biomedicines 2021, 10. [Google Scholar] [CrossRef] [PubMed]
  9. Ji A, Xu J. Neuropathic Pain: Biomolecular Intervention and Imaging Via Targeting Microglia Activation. Biomolecules 2021, 11. [Google Scholar] [CrossRef]
  10. Kowalska M, Prendecki M, Piekut T, Kozubski W, Dorszewska J. Migraine: Calcium Channels and Glia. International journal of molecular sciences 2021, 22. [Google Scholar] [CrossRef]
  11. Duarte RA, Dahmer S, Sanguinetti SY, Forde G, Duarte DP, Kobak LF. Medical Cannabis for Headache Pain: A Primer for Clinicians. Current pain and headache reports 2021, 25, 64. [Google Scholar] [CrossRef] [PubMed]
  12. Longo R, Oudshoorn A, Befus D. Cannabis for Chronic Pain: A Rapid Systematic Review of Randomized Control Trials. Pain management nursing: official journal of the American Society of Pain Management Nurses 2021, 22, 141–149. [Google Scholar] [CrossRef] [PubMed]
  13. Iannone LF, De Logu F, Geppetti P, De Cesaris F. The Role of Trp Ion Channels in Migraine and Headache. Neuroscience letters 2022, 768, 136380. [Google Scholar] [CrossRef] [PubMed]
  14. Hall OM, Broussard A, Range T, Carroll Turpin MA, Ellis S, Lim VM, et al. Novel Agents in Neuropathic Pain, the Role of Capsaicin: Pharmacology, Efficacy, Side Effects, Different Preparations. Current pain and headache reports 2020, 24, 53. [Google Scholar] [CrossRef] [PubMed]
  15. Conti P, D'Ovidio C, Conti C, Gallenga CE, Lauritano D, Caraffa A, et al. Progression in Migraine: Role of Mast Cells and Pro-Inflammatory and Anti-Inflammatory Cytokines. European journal of pharmacology 2019, 844, 87–94. [Google Scholar] [CrossRef] [PubMed]
  16. Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 1982, 298, 240–244. [Google Scholar] [CrossRef]
  17. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. Cgrp as the Target of New Migraine Therapies - Successful Translation from Bench to Clinic. Nature reviews Neurology 2018, 14, 338–350. [Google Scholar] [CrossRef] [PubMed]
  18. Kang SA, Govindarajan R. Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Neuropathic Pain in Patients with Migraine Headache. Muscle & nerve 2021, 63, 563–567. [Google Scholar] [CrossRef] [PubMed]
  19. Jovanovic F, Candido KD, Knezevic NN. The Role of the Kynurenine Signaling Pathway in Different Chronic Pain Conditions and Potential Use of Therapeutic Agents. International journal of molecular sciences 2020, 21. [Google Scholar] [CrossRef]
  20. Yilmaz N, Karaali K, Ozdem S, Turkay M, Unal A, Dora B. Elevated S100b and Neuron Specific Enolase Levels in Patients with Migraine-without Aura: Evidence for Neurodegeneration? Cellular and molecular neurobiology 2011, 31, 579–585. [Google Scholar] [CrossRef]
  21. Baka P, Escolano-Lozano F, Birklein F. Systemic Inflammatory Biomarkers in Painful Diabetic Neuropathy. Journal of diabetes and its complications 2021, 35, 108017. [Google Scholar] [CrossRef] [PubMed]
  22. Benemei S, Fusi C, Trevisan G, Geppetti P. The Trpa1 Channel in Migraine Mechanism and Treatment. British journal of pharmacology 2014, 171, 2552–2567. [Google Scholar] [CrossRef] [PubMed]
  23. Derry S, Rice AS, Cole P, Tan T, Moore RA. Topical Capsaicin (High Concentration) for Chronic Neuropathic Pain in Adults. The Cochrane database of systematic reviews 2017, 1, CD007393. [Google Scholar] [CrossRef]
  24. Wilkerson JL, Bilbrey JA, Felix JS, Makriyannis A, McMahon LR. Untapped Endocannabinoid Pharmacological Targets: Pipe Dream or Pipeline? Pharmacology, biochemistry, and behavior 2021, 206, 173192. [Google Scholar] [CrossRef]
  25. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive Peptide Release in the Extracerebral Circulation of Humans During Migraine Headache. Annals of neurology 1990, 28, 183–187. [Google Scholar] [CrossRef] [PubMed]
  26. Tuka B, Helyes Z, Markovics A, Bagoly T, Szolcsanyi J, Szabo N, et al. Alterations in Pacap-38-Like Immunoreactivity in the Plasma During Ictal and Interictal Periods of Migraine Patients. Cephalalgia: an international journal of headache 2013, 33, 1085–1095. [Google Scholar] [CrossRef]
  27. Tajti J, Uddman R, Moller S, Sundler F, Edvinsson L. Messenger Molecules and Receptor Mrna in the Human Trigeminal Ganglion. Journal of the autonomic nervous system 1999, 76, 176–183. [Google Scholar] [CrossRef]
  28. Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. Differential Distribution of Calcitonin Gene-Related Peptide and Its Receptor Components in the Human Trigeminal Ganglion. Neuroscience 2010, 169, 683–696. [Google Scholar] [CrossRef]
  29. Moskowitz MA, Reinhard JF, Jr. , Romero J, Melamed E, Pettibone DJ. Neurotransmitters and the Fifth Cranial Nerve: Is There a Relation to the Headache Phase of Migraine? Lancet 1979, 2, 883–885. [Google Scholar] [CrossRef]
  30. Liu-Chen LY, Mayberg MR, Moskowitz MA. Immunohistochemical Evidence for a Substance P-Containing Trigeminovascular Pathway to Pial Arteries in Cats. Brain research 1983, 268, 162–166. [Google Scholar] [CrossRef]
  31. Buzzi MG, Moskowitz MA. The Trigemino-Vascular System and Migraine. Pathologie-biologie 1992, 40, 313–317. [Google Scholar]
  32. Ho TW, Edvinsson L, Goadsby PJ. Cgrp and Its Receptors Provide New Insights into Migraine Pathophysiology. Nature reviews Neurology 2010, 6, 573–582. [Google Scholar] [CrossRef] [PubMed]
  33. Bigal ME, Ashina S, Burstein R, Reed ML, Buse D, Serrano D, et al. Prevalence and Characteristics of Allodynia in Headache Sufferers: A Population Study. Neurology 2008, 70, 1525–1533. [Google Scholar] [CrossRef]
  34. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. Cgrp May Play a Causative Role in Migraine. Cephalalgia: an international journal of headache 2002, 22, 54–61. [Google Scholar] [CrossRef]
  35. Negro A, Martelletti P. Gepants for the Treatment of Migraine. Expert opinion on investigational drugs 2019, 28, 555–567. [Google Scholar] [CrossRef]
  36. Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, et al. Diagnosis and Management of Migraine in Ten Steps. Nature reviews Neurology 2021, 17, 501–514. [Google Scholar] [CrossRef]
  37. Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A, et al. Migraine. Nature reviews Disease primers 2022, 8, 2. [Google Scholar] [CrossRef]
  38. Edvinsson, L. Role of Cgrp in Migraine. Handbook of experimental pharmacology 2019, 255, 121–130. [Google Scholar] [CrossRef]
  39. Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ, et al. Migraine: Integrated Approaches to Clinical Management and Emerging Treatments. Lancet 2021, 397, 1505–1518. [Google Scholar] [CrossRef]
  40. Gklinos P, Mitsikostas DD. The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions. Pharmaceuticals 2021, 14. [Google Scholar] [CrossRef]
  41. Edvinsson, L. Cgrp and Migraine: From Bench to Bedside. Revue neurologique 2021, 177, 785–790. [Google Scholar] [CrossRef] [PubMed]
  42. Gibson SJ, Polak JM, Bloom SR, Sabate IM, Mulderry PM, Ghatei MA, et al. Calcitonin Gene-Related Peptide Immunoreactivity in the Spinal Cord of Man and of Eight Other Species. The Journal of neuroscience 1984, 4, 3101–3111. [Google Scholar] [CrossRef] [PubMed]
  43. Schou WS, Ashina S, Amin FM, Goadsby PJ, Ashina M. Calcitonin Gene-Related Peptide and Pain: A Systematic Review. The journal of headache and pain 2017, 18, 34. [Google Scholar] [CrossRef]
  44. Hou Q, Barr T, Gee L, Vickers J, Wymer J, Borsani E, et al. Keratinocyte Expression of Calcitonin Gene-Related Peptide Beta: Implications for Neuropathic and Inflammatory Pain Mechanisms. Pain 2011, 152, 2036–2051. [Google Scholar] [CrossRef] [PubMed]
  45. Nicholas M, Vlaeyen JWS, Rief W, Barke A, Aziz Q, Benoliel R, et al. The Iasp Classification of Chronic Pain for Icd-11: Chronic Primary Pain. Pain 2019, 160, 28–37. [Google Scholar] [CrossRef]
  46. Birklein F, Schmelz M, Schifter S, Weber M. The Important Role of Neuropeptides in Complex Regional Pain Syndrome. Neurology 2001, 57, 2179–2184. [Google Scholar] [CrossRef]
  47. Lindqvist A, Rivero-Melian C, Turan I, Fried K. Neuropeptide- and Tyrosine Hydroxylase-Immunoreactive Nerve Fibers in Painful Morton's Neuromas. Muscle & nerve 2000, 23, 1214–1218. [Google Scholar] [CrossRef]
  48. Tajti J, Szok D, Nagy-Grocz G, Tuka B, Petrovics-Balog A, Toldi J, et al. Kynurenines and Pacap in Migraine: Medicinal Chemistry and Pathogenetic Aspects. Current medicinal chemistry 2017, 24, 1332–1349. [Google Scholar] [CrossRef] [PubMed]
  49. Bohar Z, Pardutz A, Vecsei L. Tryptophan Catabolites and Migraine. Current pharmaceutical design 2016, 22, 1013–1021. [Google Scholar] [CrossRef]
  50. Woolf CJ, Thompson SWN. The Induction and Maintenance of Central Sensitization Is Dependent on N-Methyl-D-Aspartic Acid Receptor Activation; Implications for the Treatment of Post-Injury Pain Hypersensitivity States. Pain 1991, 44, 293–299. [Google Scholar] [CrossRef]
  51. Ferrari MD, Odink J, Bos KD, Malessy MJ, Bruyn GW. Neuroexcitatory Plasma Amino Acids Are Elevated in Migraine. Neurology 1990, 40, 1582–1586. [Google Scholar] [CrossRef] [PubMed]
  52. D'Andrea G, Cananzi AR, Joseph R, Morra M, Zamberlan F, Ferro Milone F, et al. Platelet Glycine, Glutamate and Aspartate in Primary Headache. Cephalalgia: an international journal of headache 1991, 11, 197–200. [Google Scholar] [CrossRef] [PubMed]
  53. Martinez F, Castillo J, Rodriguez JR, Leira R, Noya M. Neuroexcitatory Amino Acid Levels in Plasma and Cerebrospinal Fluid During Migraine Attacks. Cephalalgia: an international journal of headache 1993, 13, 89–93. [Google Scholar] [CrossRef] [PubMed]
  54. Rajda C, Tajti J, Komoroczy R, Seres E, Klivenyi P, Vecsei L. Amino Acids in the Saliva of Patients with Migraine. Headache 1999, 39, 644–649. [Google Scholar] [CrossRef] [PubMed]
  55. Peres MF, Zukerman E, Senne Soares CA, Alonso EO, Santos BF, Faulhaber MH. Cerebrospinal Fluid Glutamate Levels in Chronic Migraine. Cephalalgia: an international journal of headache 2004, 24, 735–739. [Google Scholar] [CrossRef] [PubMed]
  56. Prescot A, Becerra L, Pendse G, Tully S, Jensen E, Hargreaves R, et al. Excitatory Neurotransmitters in Brain Regions in Interictal Migraine Patients. Molecular pain 2009, 5, 34. [Google Scholar] [CrossRef] [PubMed]
  57. Gollion, C. Cortical Excitability in Migraine: Contributions of Magnetic Resonance Imaging. Revue neurologique 2021, 177, 809–815. [Google Scholar] [CrossRef] [PubMed]
  58. Peek AL, Rebbeck T, Puts NA, Watson J, Aguila MR, Leaver AM. Brain Gaba and Glutamate Levels across Pain Conditions: A Systematic Literature Review and Meta-Analysis of 1h-Mrs Studies Using the Mrs-Q Quality Assessment Tool. NeuroImage 2020, 210, 116532. [Google Scholar] [CrossRef] [PubMed]
  59. Gecse K, Dobos D, Aranyi CS, Galambos A, Baksa D, Kocsel N, et al. Association of Plasma Tryptophan Concentration with Periaqueductal Gray Matter Functional Connectivity in Migraine Patients. Scientific reports 2022, 12, 739. [Google Scholar] [CrossRef]
  60. Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck RV, et al. Brain Stem Activation in Spontaneous Human Migraine Attacks. Nature medicine 1995, 1, 658–660. [Google Scholar] [CrossRef]
  61. Tajti J, Uddman R, Edvinsson L. Neuropeptide Localization in the "Migraine Generator" Region of the Human Brainstem. Cephalalgia: an international journal of headache 2001, 21, 96–101. [Google Scholar] [CrossRef]
  62. Weir GA, Cader MZ. New Directions in Migraine. BMC medicine 2011, 9, 116. [Google Scholar] [CrossRef]
  63. Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, et al. Familial Hemiplegic Migraine and Episodic Ataxia Type-2 Are Caused by Mutations in the Ca2+ Channel Gene Cacnl1a4. Cell 1996, 87, 543–552. [Google Scholar] [CrossRef]
  64. De Fusco M, Marconi R, Silvestri L, Atorino L, Rampoldi L, Morgante L, et al. Haploinsufficiency of Atp1a2 Encoding the Na+/K+ Pump Alpha2 Subunit Associated with Familial Hemiplegic Migraine Type 2. Nature genetics 2003, 33, 192–196. [Google Scholar] [CrossRef]
  65. Dichgans M, Freilinger T, Eckstein G, Babini E, Lorenz-Depiereux B, Biskup S, et al. Mutation in the Neuronal Voltage-Gated Sodium Channel Scn1a in Familial Hemiplegic Migraine. Lancet 2005, 366, 371–377. [Google Scholar] [CrossRef]
  66. Curto M, Lionetto L, Negro A, Capi M, Fazio F, Giamberardino MA, et al. Altered Kynurenine Pathway Metabolites in Serum of Chronic Migraine Patients. The journal of headache and pain 2015, 17, 47. [Google Scholar] [CrossRef]
  67. Tuka B, Nyari A, Cseh EK, Kortesi T, Vereb D, Tomosi F, et al. Clinical Relevance of Depressed Kynurenine Pathway in Episodic Migraine Patients: Potential Prognostic Markers in the Peripheral Plasma During the Interictal Period. The journal of headache and pain 2021, 22, 60. [Google Scholar] [CrossRef]
  68. Al-Karagholi MA, Hansen JM, Abou-Kassem D, Hansted AK, Ubhayasekera K, Bergquist J, et al. Phase 1 Study to Access Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Kynurenine in Healthy Volunteers. Pharmacology research & perspectives 2021, 9, e00741. [Google Scholar] [CrossRef]
  69. Jensen TS, Finnerup NB. Allodynia and Hyperalgesia in Neuropathic Pain: Clinical Manifestations and Mechanisms. The Lancet Neurology 2014, 13, 924–935. [Google Scholar] [CrossRef]
  70. Wallace MS, Lam V, Schettler J. Ngx426, an Oral Ampa-Kainate Antagonist, Is Effective in Human Capsaicin-Induced Pain and Hyperalgesia. Pain medicine 2012, 13, 1601–1610. [Google Scholar] [CrossRef]
  71. Chappell AS, Iyengar S, Lobo ED, Prucka WR. Results from Clinical Trials of a Selective Ionotropic Glutamate Receptor 5 (Iglur5) Antagonist, Ly5454694 Tosylate, in 2 Chronic Pain Conditions. Pain 2014, 155, 1140–1149. [Google Scholar] [CrossRef]
  72. Wallace M, White A, Grako KA, Lane R, Cato AJ, Snodgrass HR. Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study: Investigation of the Safety, Pharmacokinetics, and Antihyperalgesic Activity of L-4-Chlorokynurenine in Healthy Volunteers. Scandinavian journal of pain 2017, 17, 243–251. [Google Scholar] [CrossRef]
  73. Alexander GM, Reichenberger E, Peterlin BL, Perreault MJ, Grothusen JR, Schwartzman RJ. Plasma Amino Acids Changes in Complex Regional Pain Syndrome. Pain research and treatment 2013, 2013, 742407. [Google Scholar] [CrossRef]
  74. Barjandi G, Louca Jounger S, Lofgren M, Bileviciute-Ljungar I, Kosek E, Ernberg M. Plasma Tryptophan and Kynurenine in Females with Temporomandibular Disorders and Fibromyalgia-an Exploratory Pilot Study. Journal of oral rehabilitation 2020, 47, 150–157. [Google Scholar] [CrossRef]
  75. Csati A, Tajti J, Tuka B, Edvinsson L, Warfvinge K. Calcitonin Gene-Related Peptide and Its Receptor Components in the Human Sphenopalatine Ganglion -- Interaction with the Sensory System. Brain research 2012, 1435, 29–39. [Google Scholar] [CrossRef]
  76. Edvinsson L, Haanes KA, Warfvinge K. Does Inflammation Have a Role in Migraine? Nature reviews Neurology 2019, 15, 483–490. [Google Scholar] [CrossRef]
  77. Teepker M, Munk K, Mylius V, Haag A, Moller JC, Oertel WH, et al. Serum Concentrations of S100b and Nse in Migraine. Headache 2009, 49, 245–252. [Google Scholar] [CrossRef]
  78. Celikbilek A, Sabah S, Tanik N, Ak H, Atalay T, Yilmaz N. Is Serum S100b Protein an Useful Biomarker in Migraine? Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2014, 35, 1197–1201. [Google Scholar] [CrossRef]
  79. Kwok YH, Swift JE, Gazerani P, Rolan P. A Double-Blind, Randomized, Placebo-Controlled Pilot Trial to Determine the Efficacy and Safety of Ibudilast, a Potential Glial Attenuator, in Chronic Migraine. Journal of pain research 2016, 9, 899–907. [Google Scholar] [CrossRef]
  80. Riesco N, Cernuda-Morollon E, Martinez-Camblor P, Perez-Pereda S, Pascual J. Peripheral, Interictal Serum S100b Levels Are Not Increased in Chronic Migraine Patients. Headache 2020, 60, 1705–1711. [Google Scholar] [CrossRef]
  81. Gonen M, Ozdogan S, Balgetir F, Demir CF, Aytac E, Mungen B. S100b and Neuron-Specific Enolase Levels in Episodic and Chronic Migraine. Acta neurologica Scandinavica 2021, 143, 298–302. [Google Scholar] [CrossRef] [PubMed]
  82. Coull JA, Boudreau D, Bachand K, Prescott SA, Nault F, Sik A, et al. Trans-Synaptic Shift in Anion Gradient in Spinal Lamina I Neurons as a Mechanism of Neuropathic Pain. Nature 2003, 424, 938–942. [Google Scholar] [CrossRef]
  83. Coull JA, Beggs S, Boudreau D, Boivin D, Tsuda M, Inoue K, et al. Bdnf from Microglia Causes the Shift in Neuronal Anion Gradient Underlying Neuropathic Pain. Nature 2005, 438, 1017–1021. [Google Scholar] [CrossRef] [PubMed]
  84. Trang T, Beggs S, Salter MW. Brain-Derived Neurotrophic Factor from Microglia: A Molecular Substrate for Neuropathic Pain. Neuron glia biology 2011, 7, 99–108. [Google Scholar] [CrossRef] [PubMed]
  85. Tsuda, M. Microglia in the Spinal Cord and Neuropathic Pain. Journal of diabetes investigation 2016, 7, 17–26. [Google Scholar] [CrossRef] [PubMed]
  86. Suter, MR. Microglial Role in the Development of Chronic Pain. Current opinion in anaesthesiology 2016, 29, 584–589. [Google Scholar] [CrossRef] [PubMed]
  87. Haight ES, Forman TE, Cordonnier SA, James ML, Tawfik VL. Microglial Modulation as a Target for Chronic Pain: From the Bench to the Bedside and Back. Anesthesia and analgesia 2019, 128, 737–746. [Google Scholar] [CrossRef] [PubMed]
  88. Ji RR, Berta T, Nedergaard M. Glia and Pain: Is Chronic Pain a Gliopathy? Pain 2013, 154 (Suppl 1), S10–S28. [Google Scholar] [CrossRef] [PubMed]
  89. Block, L. Glial Dysfunction and Persistent Neuropathic Postsurgical Pain. Scandinavian journal of pain 2016, 10, 74–81. [Google Scholar] [CrossRef]
  90. Banati RB, Cagnin A, Brooks DJ, Gunn RN, Myers R, Jones T, et al. Long-Term Trans-Synaptic Glial Responses in the Human Thalamus after Peripheral Nerve Injury. Neuroreport 2001, 12, 3439–3442. [Google Scholar] [CrossRef]
  91. Green JM, Sundman MH, Chou YH. Opioid-Induced Microglia Reactivity Modulates Opioid Reward, Analgesia, and Behavior. Neuroscience and biobehavioral reviews 2022, 135, 104544. [Google Scholar] [CrossRef] [PubMed]
  92. Machelska H, Celik MO. Opioid Receptors in Immune and Glial Cells-Implications for Pain Control. Frontiers in immunology 2020, 11, 300. [Google Scholar] [CrossRef] [PubMed]
  93. Maarrawi J, Peyron R, Mertens P, Costes N, Magnin M, Sindou M, et al. Motor Cortex Stimulation for Pain Control Induces Changes in the Endogenous Opioid System. Neurology 2007, 69, 827–834. [Google Scholar] [CrossRef]
  94. Loggia ML, Chonde DB, Akeju O, Arabasz G, Catana C, Edwards RR, et al. Evidence for Brain Glial Activation in Chronic Pain Patients. Brain: a journal of neurology 2015, 138, 604–615. [Google Scholar] [CrossRef] [PubMed]
  95. Anand P, Shenoy R, Palmer JE, Baines AJ, Lai RY, Robertson J, et al. Clinical Trial of the P38 Map Kinase Inhibitor Dilmapimod in Neuropathic Pain Following Nerve Injury. European journal of pain 2011, 15, 1040–1048. [Google Scholar] [CrossRef] [PubMed]
  96. Landry RP, Jacobs VL, Romero-Sandoval EA, DeLeo JA. Propentofylline, a Cns Glial Modulator Does Not Decrease Pain in Post-Herpetic Neuralgia Patients: In Vitro Evidence for Differential Responses in Human and Rodent Microglia and Macrophages. Experimental neurology 2012, 234, 340–350. [Google Scholar] [CrossRef] [PubMed]
  97. Ostenfeld T, Krishen A, Lai RY, Bullman J, Green J, Anand P, et al. A Randomized, Placebo-Controlled Trial of the Analgesic Efficacy and Safety of the P38 Map Kinase Inhibitor, Losmapimod, in Patients with Neuropathic Pain from Lumbosacral Radiculopathy. The Clinical journal of pain 2015, 31, 283–293. [Google Scholar] [CrossRef] [PubMed]
  98. Syngle A, Verma I, Krishan P, Garg N, Syngle V. Minocycline Improves Peripheral and Autonomic Neuropathy in Type 2 Diabetes: Mind Study. Neurological sciences 2014, 35, 1067–1073. [Google Scholar] [CrossRef] [PubMed]
  99. Sumitani M, Ueda H, Hozumi J, Inoue R, Kogure T, Yamada Y. Minocycline Does Not Decrease Intensity of Neuropathic Pain Intensity, but Does Improve Its Affective Dimension. Journal of pain & palliative care pharmacotherapy 2016, 30, 31–35. [Google Scholar] [CrossRef]
  100. Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, Wilmore D, et al. Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study. Journal of the National Cancer Institute 1988, 80, 1039–1044. [Google Scholar] [CrossRef]
  101. Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, et al. Clinical Pharmacology of Recombinant Human Tumor Necrosis Factor in Patients with Advanced Cancer. Journal of clinical oncology 1987, 5, 1942–1951. [Google Scholar] [CrossRef] [PubMed]
  102. Schiller JH, Storer BE, Witt PL, Alberti D, Tombes MB, Arzoomanian R, et al. Biological and Clinical Effects of Intravenous Tumor Necrosis Factor-Alpha Administered Three Times Weekly. Cancer research 1991, 51, 1651–1658. [Google Scholar]
  103. Smith, RS. The Cytokine Theory of Headache. Medical hypotheses 1992, 39, 168–174. [Google Scholar] [CrossRef]
  104. van Hilten JJ, Ferrari MD, Van der Meer JW, Gijsman HJ, Looij BJ, Jr. Plasma Interleukin-1, Tumour Necrosis Factor and Hypothalamic-Pituitary-Adrenal Axis Responses During Migraine Attacks. Cephalalgia 1991, 11, 65–67. [Google Scholar] [CrossRef]
  105. Mueller L, Gupta AK, Stein TP. Deficiency of Tumor Necrosis Factor Alpha in a Subclass of Menstrual Migraineurs. Headache 2001, 41, 129–137. [Google Scholar] [CrossRef]
  106. Empl M, Sostak P, Riedel M, Schwarz M, Muller N, Forderreuther S, et al. Decreased Stnf-Ri in Migraine Patients? Cephalalgia: an international journal of headache 2003, 23, 55–58. [Google Scholar] [CrossRef] [PubMed]
  107. Perini F, D'Andrea G, Galloni E, Pignatelli F, Billo G, Alba S, et al. Plasma Cytokine Levels in Migraineurs and Controls. Headache 2005, 45, 926–931. [Google Scholar] [CrossRef] [PubMed]
  108. Sarchielli P, Alberti A, Baldi A, Coppola F, Rossi C, Pierguidi L, et al. Proinflammatory Cytokines, Adhesion Molecules, and Lymphocyte Integrin Expression in the Internal Jugular Blood of Migraine Patients without Aura Assessed Ictally. Headache 2006, 46, 200–207. [Google Scholar] [CrossRef]
  109. Fidan I, Yuksel S, Ymir T, Irkec C, Aksakal FN. The Importance of Cytokines, Chemokines and Nitric Oxide in Pathophysiology of Migraine. Journal of neuroimmunology 2006, 171, 184–188. [Google Scholar] [CrossRef]
  110. Tanure MT, Gomez RS, Hurtado RC, Teixeira AL, Domingues RB. Increased Serum Levels of Brain-Derived Neurotropic Factor During Migraine Attacks: A Pilot Study. The journal of headache and pain 2010, 11, 427–430. [Google Scholar] [CrossRef]
  111. Uzar E, Evliyaoglu O, Yucel Y, Ugur Cevik M, Acar A, Guzel I, et al. Serum Cytokine and Pro-Brain Natriuretic Peptide (Bnp) Levels in Patients with Migraine. European review for medical and pharmacological sciences 2011, 15, 1111–1116. [Google Scholar]
  112. Wang F, He Q, Ren Z, Li F, Chen W, Lin X, et al. Association of Serum Levels of Intercellular Adhesion Molecule-1 and Interleukin-6 with Migraine. Neurological sciences 2015, 36, 535–540. [Google Scholar] [CrossRef] [PubMed]
  113. Yucel M, Kotan D, Gurol Ciftci G, Ciftci IH, Cikriklar HI. Serum Levels of Endocan, Claudin-5 and Cytokines in Migraine. European review for medical and pharmacological sciences 2016, 20, 930–936. [Google Scholar]
  114. Bostrom A, Scheele D, Stoffel-Wagner B, Honig F, Chaudhry SR, Muhammad S, et al. Saliva Molecular Inflammatory Profiling in Female Migraine Patients Responsive to Adjunctive Cervical Non-Invasive Vagus Nerve Stimulation: The Moxy Study. Journal of translational medicine 2019, 17, 53. [Google Scholar] [CrossRef] [PubMed]
  115. Togha M, Razeghi Jahromi S, Ghorbani Z, Ghaemi A, Rafiee P. Evaluation of Inflammatory State in Migraineurs: A Case-Control Study. Iranian journal of allergy, asthma, and immunology 2020, 19, 83–90. [Google Scholar] [CrossRef] [PubMed]
  116. Bougea A, Spantideas N, Galanis P, Katsika P, Boufidou F, Voskou P, et al. Salivary Inflammatory Markers in Tension Type Headache and Migraine: The Salhead Cohort Study. Neurological sciences 2020, 41, 877–884. [Google Scholar] [CrossRef]
  117. Donder A, Cafer V, Yilmaz A, Aslanhan H, Arikanoglu A. Investigation of Serum Vaspin, Visfatin, Chemerin and Il-18 Levels in Migraine Patients. Arquivos de neuro-psiquiatria 2021, 79, 789–794. [Google Scholar] [CrossRef] [PubMed]
  118. Bo SH, Davidsen EM, Gulbrandsen P, Dietrichs E, Bovim G, Stovner LJ, et al. Cerebrospinal Fluid Cytokine Levels in Migraine, Tension-Type Headache and Cervicogenic Headache. Cephalalgia 2009, 29, 365–372. [Google Scholar] [CrossRef]
  119. Yilmaz IA, Ozge A, Erdal ME, Edgunlu TG, Cakmak SE, Yalin OO. Cytokine Polymorphism in Patients with Migraine: Some Suggestive Clues of Migraine and Inflammation. Pain medicine 2010, 11, 492–497. [Google Scholar] [CrossRef]
  120. Schurks M, Rist PM, Zee RY, Chasman DI, Kurth T. Tumour Necrosis Factor Gene Polymorphisms and Migraine: A Systematic Review and Meta-Analysis. Cephalalgia 2011, 31, 1381–1404. [Google Scholar] [CrossRef]
  121. Liu R, Ma M, Cui M, Dong Z, Wang X, Zhang W, et al. Effects of Tumor Necrosis Factor-Beta (Tnf-Beta) 252a>G Polymorphism on the Development of Migraine: A Meta-Analysis. PloS one 2014, 9, e100189. [Google Scholar] [CrossRef] [PubMed]
  122. Abdolahi M, Tafakhori A, Togha M, Okhovat AA, Siassi F, Eshraghian MR, et al. The Synergistic Effects of Omega-3 Fatty Acids and Nano-Curcumin Supplementation on Tumor Necrosis Factor (Tnf)-Alpha Gene Expression and Serum Level in Migraine Patients. Immunogenetics 2017, 69, 371–378. [Google Scholar] [CrossRef] [PubMed]
  123. Abdolahi M, Sarraf P, Javanbakht MH, Honarvar NM, Hatami M, Soveyd N, et al. A Novel Combination of Omega-3 Fatty Acids and Nano-Curcumin Modulates Interleukin-6 Gene Expression and High Sensitivity C-Reactive Protein Serum Levels in Patients with Migraine: A Randomized Clinical Trial Study. CNS & neurological disorders drug targets 2018, 17, 430–438. [Google Scholar] [CrossRef] [PubMed]
  124. Ramezani M, Komaki A, Eftekharian MM, Mazdeh M, Ghafouri-Fard S. Over-Expression of Il-6 Coding Gene in the Peripheral Blood of Migraine with Aura Patients. Human antibodies 2021, 29, 203–207. [Google Scholar] [CrossRef]
  125. Taheri M, Nicknafs F, Hesami O, Javadi A, Arsang-Jang S, Sayad A, et al. Differential Expression of Cytokine-Coding Genes among Migraine Patients with and without Aura and Normal Subjects. Journal of molecular neuroscience 2021, 71, 1197–1204. [Google Scholar] [CrossRef]
  126. Hamad N, Alzoubi KH, Swedan SF, Khabour OF, El-Salem K. Association between Tumor Necrosis Factor Alpha and Lymphotoxin Alpha Gene Polymorphisms and Migraine Occurrence among Jordanians. Neurological sciences 2021, 42, 3625–3630. [Google Scholar] [CrossRef] [PubMed]
  127. Geng C, Yang Z, Xu P, Zhang H. Aberrations in Peripheral Inflammatory Cytokine Levels in Migraine: A Systematic Review and Meta-Analysis. Journal of clinical neuroscience 2022, 98, 213–218. [Google Scholar] [CrossRef] [PubMed]
  128. Uceyler N, Kafke W, Riediger N, He L, Necula G, Toyka KV, et al. Elevated Proinflammatory Cytokine Expression in Affected Skin in Small Fiber Neuropathy. Neurology 2010, 74, 1806–1813. [Google Scholar] [CrossRef]
  129. Leung L, Cahill CM. Tnf-Alpha and Neuropathic Pain--a Review. Journal of neuroinflammation 2010, 7, 27. [Google Scholar] [CrossRef]
  130. Cohen SP, Mao J. Neuropathic Pain: Mechanisms and Their Clinical Implications. BMJ 2014, 348, f7656. [Google Scholar] [CrossRef]
  131. Sommer C, Leinders M, Uceyler N. Inflammation in the Pathophysiology of Neuropathic Pain. Pain 2018, 159, 595–602. [Google Scholar] [CrossRef] [PubMed]
  132. Empl M, Renaud S, Erne B, Fuhr P, Straube A, Schaeren-Wiemers N, et al. Tnf-Alpha Expression in Painful and Nonpainful Neuropathies. Neurology 2001, 56, 1371–1377. [Google Scholar] [CrossRef] [PubMed]
  133. Uceyler N, Rogausch JP, Toyka KV, Sommer C. Differential Expression of Cytokines in Painful and Painless Neuropathies. Neurology 2007, 69, 42–49. [Google Scholar] [CrossRef] [PubMed]
  134. Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A. Microvascular Reactivity and Inflammatory Cytokines in Painful and Painless Peripheral Diabetic Neuropathy. The Journal of clinical endocrinology and metabolism 2009, 94, 2157–2163. [Google Scholar] [CrossRef] [PubMed]
  135. Purwata, TE. High Tnf-Alpha Plasma Levels and Macrophages Inos and Tnf-Alpha Expression as Risk Factors for Painful Diabetic Neuropathy. Journal of pain research 2011, 4, 169–175. [Google Scholar] [CrossRef] [PubMed]
  136. Ohtori S, Miyagi M, Eguchi Y, Inoue G, Orita S, Ochiai N, et al. Epidural Administration of Spinal Nerves with the Tumor Necrosis Factor-Alpha Inhibitor, Etanercept, Compared with Dexamethasone for Treatment of Sciatica in Patients with Lumbar Spinal Stenosis: A Prospective Randomized Study. Spine 2012, 37, 439–444. [Google Scholar] [CrossRef] [PubMed]
  137. Ohtori S, Miyagi M, Eguchi Y, Inoue G, Orita S, Ochiai N, et al. Efficacy of Epidural Administration of Anti-Interleukin-6 Receptor Antibody onto Spinal Nerve for Treatment of Sciatica. European spine journal 2012, 21, 2079–2084. [Google Scholar] [CrossRef]
  138. Ostenfeld T, Krishen A, Lai RY, Bullman J, Baines AJ, Green J, et al. Analgesic Efficacy and Safety of the Novel P38 Map Kinase Inhibitor, Losmapimod, in Patients with Neuropathic Pain Following Peripheral Nerve Injury: A Double-Blind, Placebo-Controlled Study. European journal of pain 2013, 17, 844–857. [Google Scholar] [CrossRef] [PubMed]
  139. Uceyler N, Riediger N, Kafke W, Sommer C. Differential Gene Expression of Cytokines and Neurotrophic Factors in Nerve and Skin of Patients with Peripheral Neuropathies. Journal of neurology 2015, 262, 203–212. [Google Scholar] [CrossRef]
  140. Herder C, Bongaerts BW, Rathmann W, Heier M, Kowall B, Koenig W, et al. Differential Association between Biomarkers of Subclinical Inflammation and Painful Polyneuropathy: Results from the Kora F4 Study. Diabetes care 2015, 38, 91–96. [Google Scholar] [CrossRef]
  141. Allison DJ, Thomas A, Beaudry K, Ditor DS. Targeting Inflammation as a Treatment Modality for Neuropathic Pain in Spinal Cord Injury: A Randomized Clinical Trial. Journal of neuroinflammation 2016, 13, 152. [Google Scholar] [CrossRef] [PubMed]
  142. Ziegler D, Strom A, Bonhof GJ, Kannenberg JM, Heier M, Rathmann W, et al. Deficits in Systemic Biomarkers of Neuroinflammation and Growth Factors Promoting Nerve Regeneration in Patients with Type 2 Diabetes and Polyneuropathy. BMJ open diabetes research & care 2019, 7, e000752. [Google Scholar] [CrossRef] [PubMed]
  143. Saxena AK, Bhardwaj N, Chilkoti GT, Malik A, Thakur GK, Bajaj M, et al. Modulation of Mrna Expression of Il-6 and Mtorc1 and Efficacy and Feasibility of an Integrated Approach Encompassing Cognitive Behavioral Therapy Along with Pregabalin for Management of Neuropathic Pain in Postherpetic Neuralgia: A Pilot Study. Pain medicine 2021, 22, 2276–2282. [Google Scholar] [CrossRef] [PubMed]
  144. Benemei S, De Cesaris F, Fusi C, Rossi E, Lupi C, Geppetti P. Trpa1 and Other Trp Channels in Migraine. The journal of headache and pain 2013, 14, 71. [Google Scholar] [CrossRef] [PubMed]
  145. Benemei S, Dussor G. Trp Channels and Migraine: Recent Developments and New Therapeutic Opportunities. Pharmaceuticals 2019, 12. [Google Scholar] [CrossRef] [PubMed]
  146. Diamond S, Freitag F, Phillips SB, Bernstein JE, Saper JR. Intranasal Civamide for the Acute Treatment of Migraine Headache. Cephalalgia: an international journal of headache 2000, 20, 597–602. [Google Scholar] [CrossRef] [PubMed]
  147. Fusco BM, Barzoi G, Agro F. Repeated Intranasal Capsaicin Applications to Treat Chronic Migraine. British journal of anaesthesia 2003, 90, 812. [Google Scholar] [CrossRef] [PubMed]
  148. Cianchetti, C. Capsaicin Jelly against Migraine Pain. International journal of clinical practice 2010, 64, 457–459. [Google Scholar] [CrossRef]
  149. Borhani Haghighi A, Motazedian S, Rezaii R, Mohammadi F, Salarian L, Pourmokhtari M, et al. Cutaneous Application of Menthol 10% Solution as an Abortive Treatment of Migraine without Aura: A Randomised, Double-Blind, Placebo-Controlled, Crossed-over Study. International journal of clinical practice 2010, 64, 451–456. [Google Scholar] [CrossRef] [PubMed]
  150. Del Fiacco M, Quartu M, Boi M, Serra MP, Melis T, Boccaletti R, et al. Trpv1, Cgrp and Sp in Scalp Arteries of Patients Suffering from Chronic Migraine. Journal of neurology, neurosurgery, and psychiatry 2015, 86, 393–397. [Google Scholar] [CrossRef]
  151. Yakubova A, Davidyuk Y, Tohka J, Khayrutdinova O, Kudryavtsev I, Nurkhametova D, et al. Searching for Predictors of Migraine Chronification: A Pilot Study of 1911a>G Polymorphism of Trpv1 Gene in Episodic Versus Chronic Migraine. Journal of molecular neuroscience : MN 2021, 71, 618–624. [Google Scholar] [CrossRef] [PubMed]
  152. Carreno O, Corominas R, Fernandez-Morales J, Camina M, Sobrido MJ, Fernandez-Fernandez JM, et al. Snp Variants within the Vanilloid Trpv1 and Trpv3 Receptor Genes Are Associated with Migraine in the Spanish Population. American journal of medical genetics Part B, Neuropsychiatric genetics 2012, 159B, 94–103. [Google Scholar] [CrossRef] [PubMed]
  153. Fernandez-Carvajal A, Gonzalez-Muniz R, Fernandez-Ballester G, Ferrer-Montiel A. Investigational Drugs in Early Phase Clinical Trials Targeting Thermotransient Receptor Potential (Thermotrp) Channels. Expert opinion on investigational drugs 2020, 29, 1209–1222. [Google Scholar] [CrossRef] [PubMed]
  154. Basso L, Altier C. Transient Receptor Potential Channels in Neuropathic Pain. Current opinion in pharmacology 2017, 32, 9–15. [Google Scholar] [CrossRef]
  155. Julius, D. Trp Channels and Pain. Annual review of cell and developmental biology 2013, 29, 355–384. [Google Scholar] [CrossRef] [PubMed]
  156. Jancso G, Kiraly E, Jancso-Gabor A. Pharmacologically Induced Selective Degeneration of Chemosensitive Primary Sensory Neurones. Nature 1977, 270, 741–743. [Google Scholar] [CrossRef]
  157. Jancso N, Jancso-Gabor A, Szolcsanyi J. Direct Evidence for Neurogenic Inflammation and Its Prevention by Denervation and by Pretreatment with Capsaicin. British journal of pharmacology and chemotherapy 1967, 31, 138–151. [Google Scholar] [CrossRef] [PubMed]
  158. Bonezzi C, Costantini A, Cruccu G, Fornasari DMM, Guardamagna V, Palmieri V, et al. Capsaicin 8% Dermal Patch in Clinical Practice: An Expert Opinion. Expert opinion on pharmacotherapy 2020, 21, 1377–1387. [Google Scholar] [CrossRef] [PubMed]
  159. Giaccari LG, Aurilio C, Coppolino F, Pace MC, Passsavanti MB, Pota V, et al. Capsaicin 8% Patch and Chronic Postsurgical Neuropathic Pain. Journal of personalized medicine 2021, 11. [Google Scholar] [CrossRef]
  160. Goncalves D, Rebelo V, Barbosa P, Gomes A. 8% Capsaicin Patch in Treatment of Peripheral Neuropathic Pain. Pain physician 2020, 23, E541–E548. [Google Scholar]
  161. Privitera R, Anand P. Capsaicin 8% Patch Qutenza and Other Current Treatments for Neuropathic Pain in Chemotherapy-Induced Peripheral Neuropathy (Cipn). Current opinion in supportive and palliative care 2021, 15, 125–131. [Google Scholar] [CrossRef] [PubMed]
  162. Brindisi M, Borrelli G, Brogi S, Grillo A, Maramai S, Paolino M, et al. Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain. ChemMedChem 2018, 13, 2090–2103. [Google Scholar] [CrossRef]
  163. Greco R, Demartini C, Zanaboni AM, Francavilla M, De Icco R, Ahmad L, et al. The Endocannabinoid System and Related Lipids as Potential Targets for the Treatment of Migraine-Related Pain. Headache. [CrossRef]
  164. Russo, EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis and cannabinoid research 2016, 1, 154–165. [Google Scholar] [CrossRef] [PubMed]
  165. Cupini LM, Bari M, Battista N, Argiro G, Finazzi-Agro A, Calabresi P, et al. Biochemical Changes in Endocannabinoid System Are Expressed in Platelets of Female but Not Male Migraineurs. Cephalalgia 2006, 26, 277–281. [Google Scholar] [CrossRef] [PubMed]
  166. Sarchielli P, Pini LA, Coppola F, Rossi C, Baldi A, Mancini ML, et al. Endocannabinoids in Chronic Migraine: Csf Findings Suggest a System Failure. Neuropsychopharmacology 2007, 32, 1384–1390. [Google Scholar] [CrossRef] [PubMed]
  167. Cupini LM, Costa C, Sarchielli P, Bari M, Battista N, Eusebi P, et al. Degradation of Endocannabinoids in Chronic Migraine and Medication Overuse Headache. Neurobiology of disease 2008, 30, 186–189. [Google Scholar] [CrossRef]
  168. Rossi C, Pini LA, Cupini ML, Calabresi P, Sarchielli P. Endocannabinoids in Platelets of Chronic Migraine Patients and Medication-Overuse Headache Patients: Relation with Serotonin Levels. European journal of clinical pharmacology 2008, 64, 1–8. [Google Scholar] [CrossRef]
  169. Van der Schueren BJ, Van Laere K, Gerard N, Bormans G, De Hoon JN. Interictal Type 1 Cannabinoid Receptor Binding Is Increased in Female Migraine Patients. Headache 2012, 52, 433–440. [Google Scholar] [CrossRef] [PubMed]
  170. Perrotta A, Arce-Leal N, Tassorelli C, Gasperi V, Sances G, Blandini F, et al. Acute Reduction of Anandamide-Hydrolase (Faah) Activity Is Coupled with a Reduction of Nociceptive Pathways Facilitation in Medication-Overuse Headache Subjects after Withdrawal Treatment. Headache 2012, 52, 1350–1361. [Google Scholar] [CrossRef] [PubMed]
  171. Gouveia-Figueira S, Goldin K, Hashemian SA, Lindberg A, Persson M, Nording ML, et al. Plasma Levels of the Endocannabinoid Anandamide, Related N-Acylethanolamines and Linoleic Acid-Derived Oxylipins in Patients with Migraine. Prostaglandins, leukotrienes, and essential fatty acids 2017, 120, 15–24. [Google Scholar] [CrossRef]
  172. Juhasz G, Lazary J, Chase D, Pegg E, Downey D, Toth ZG, et al. Variations in the Cannabinoid Receptor 1 Gene Predispose to Migraine. Neuroscience letters 2009, 461, 116–120. [Google Scholar] [CrossRef] [PubMed]
  173. Juhasz G, Csepany E, Magyar M, Edes AE, Eszlari N, Hullam G, et al. Variants in the Cnr1 Gene Predispose to Headache with Nausea in the Presence of Life Stress. Genes, brain, and behavior 2017, 16, 384–393. [Google Scholar] [CrossRef] [PubMed]
  174. Oliveira AB, Ribeiro RT, Mello MT, Tufik S, Peres MFP. Anandamide Is Related to Clinical and Cardiorespiratory Benefits of Aerobic Exercise Training in Migraine Patients: A Randomized Controlled Clinical Trial. Cannabis and cannabinoid research 2019, 4, 275–284. [Google Scholar] [CrossRef] [PubMed]
  175. Greco R, Demartini C, Zanaboni AM, Tumelero E, Icco R, Sances G, et al. Peripheral Changes of Endocannabinoid System Components in Episodic and Chronic Migraine Patients: A Pilot Study. Cephalalgia 2021, 41, 185–196. [Google Scholar] [CrossRef] [PubMed]
  176. De Icco R, Greco R, Demartini C, Vergobbi P, Zanaboni A, Tumelero E, et al. Spinal Nociceptive Sensitization and Plasma Palmitoylethanolamide Levels During Experimentally Induced Migraine Attacks. Pain 2021, 162, 2376–2385. [Google Scholar] [CrossRef] [PubMed]
  177. Keimpema E, Di Marzo V, Harkany T. Biological Basis of Cannabinoid Medicines. Science 2021, 374, 1449–1450. [Google Scholar] [CrossRef] [PubMed]
  178. Maldonado R, Banos JE, Cabanero D. The Endocannabinoid System and Neuropathic Pain. Pain 2016, 157 (Suppl 1), S23–S32. [Google Scholar] [CrossRef] [PubMed]
  179. Conigliaro R, Drago V, Foster PS, Schievano C, Di Marzo V. Use of Palmitoylethanolamide in the Entrapment Neuropathy of the Median in the Wrist. Minerva medica 2011, 102, 141–147. [Google Scholar]
  180. Andresen SR, Bing J, Hansen RM, Biering-Sorensen F, Johannesen IL, Hagen EM, et al. Ultramicronized Palmitoylethanolamide in Spinal Cord Injury Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Trial. Pain 2016, 157, 2097–2103. [Google Scholar] [CrossRef]
Table 1. Selected human clinical data related to CGRP in migraine and neuropathic pain.
Table 1. Selected human clinical data related to CGRP in migraine and neuropathic pain.
Migraine ref.
EM CM
M0 MA
Ictally Interictally Ictally Interictally Ictally Interictally
↑(plasma from external jugular vein) nd nd nd nd nd [25]
↑(plasma from cubital vein) nd nd nd nd nd [26]
Neuropathic pain ref.
Peripheral NP Central NP
↑(nerve fibers) painful neuroma nd [47]
↑(serum) CRPS nd [46]
↑(keratinocyta) PHN nd [44]
↑: increased concentration; ↓: decreased concentration; Abbreviations: CGRP: calcitonin gene-related peptide, CM: chronic migraine, CRPS: complex regional pain syndrome, EM: episodic migraine, M0: migraine without aura, MA: migraine with aura, NP: neuropathic pain, nd: no data available, PHN: postherpetic neuralgia.
Table 2. Selected human clinical data related to the glutamate and the kynurenine system in migraine and neuropathic pain.
Table 2. Selected human clinical data related to the glutamate and the kynurenine system in migraine and neuropathic pain.
Migraine ref.
EM CM
M0 MA
Ictally Interictally Ictally Interictally
↑glutamic acid (plasma) ↑glutamic acid (plasma) ↑glutamic acid (plasma) ↑glutamic acid (plasma) nd [51]
nd nd ↑glutamic acid (platelet) ↑glutamic acid (platelet) nd [52]
↓glutamic acid (plasma) nd ↓glutamic (plasma) nd nd [53]
↑glutamic acid (CSF) nd ↑glutamic acid (CSF) nd nd [53]
nd ↑glutamic acid (saliva) nd nd nd [54]
nd nd nd nd ↑glutamic acid (CSF) [55]
nd nd nd nd ↓KYNA (serum) [66]
nd ↓L-KYN, KYNA, anthranilic acid, picolinic acid, 5-hydroxy-indoleaceticacid (plasma) nd nd nd [67]
Neuropathic pain ref.
Peripheral NP Central NP
↑L-glutamate (plasma) in CRPS
↓L-TRP (plasma) in CRPS
↑the KYN/TRP ratio		 nd [73]
negative correlation (TRP serum level and pain intensity) in temporomandibular disorders myalgia
positive correlation the KYN/TRP ratio and pain intensity) in temporomandibular disorders myalgia		 nd [74]
↑: increased concentration; ↓: decreased concentration; Abbreviations: CM: chronic migraine, CRPS: complex regional pain syndrome, CSF: cerebrospinal fluid, EM: episodic migraine, KYNA: kynurenic acid, L-KYN: L-kynurenine, M0: migraine without aura, MA: migraine with aura, NP: neuropathic pain, nd: no data available, Trp: tryptophan.
Table 3. Selected human clinical data related to glia function in migraine and neuropathic pain.
Table 3. Selected human clinical data related to glia function in migraine and neuropathic pain.
Migraine ref.
EM CM
M0 MA
Ictally Interictally Ictally Interictally
↑S100B (serum) ↑S100B (serum) nd nd nd [77]
↑S100B (serum) ↑S100B (serum) nd nd nd [20]
nd ↓S100B (serum) nd ↓S100B (serum) nd [78]
nd ↑S100B (serum) nd nd ↑S100B (serum) [80]
nd ↑S100B (serum) nd nd ↑S100B (serum) [81]
Neuropathic pain ref.
Peripheral NP Central NP
activated glial cells (PET):
in thalamus, anterior and posterior central gyrus, paracentral lobule		 nd [90]
[9]
↑: increased concentration; ↓: decreased concentration; Abbreviations: CM: chronic migraine, CRPS: complex regional pain syndrome, CSF: cerebrospinal fluid, EM: episodic migraine, KYNA: kynurenic acid, L-KYN: L-kynurenine, M0: migraine without aura, MA: migraine with aura, NP: neuropathic pain, nd: no data available, PET: positron emission tomography.
Table 4. Selected human clinical data related to cytokines in migraine and neuropathic pain.
Table 4. Selected human clinical data related to cytokines in migraine and neuropathic pain.
Migraine ref.
EM CM
M0 MA
Ictally Interictally Ictally Interictally
=IL-1, TNF (plasma) =IL-1, TNF (plasma) =IL-1, TNF (plasma) =IL-1, TNF (plasma) nd [104]
↑IL-6 (urine)
=IL-1beta (urine)
↓TNFalpha (urine)		 ↑IL-6 (urine)
=IL-1beta (urine)
↓TNFalpha (urine)		 nd nd nd [105]
nd =TNFalpha, IL-6 (serum) nd =TNFalpha, IL-6 (serum) nd [106]
nd ↑TNFalpha, IL-1beta, IL-10 (plasma) nd nd nd [106]
↑TNFalpha (serum) nd nd nd nd [108]
↑IL-10, IL-6 (serum) nd nd nd nd [109]
↑IL-1 receptor antagonist (CSF) nd ↑IL-1 receptor antagonist (CSF) nd nd [108]
=TNFalpha (serum) nd nd nd nd [110]
↑IL-1beta, IL-6 (serum)
↑Il-10 (serum)		 nd nd nd nd [111]
↑IL-6 (serum) nd ↑IL-6 (serum) nd nd [112]
↑TNFalpha , IL-1beta, IL-6 (serum) nd nd nd nd [113]
nd ↓IL-6 (mRNA and serum) nd nd nd [114]
nd nd nd nd ↑TNFalpha, L-6 (serum) [115]
nd ↑IL-1beta (saliva) nd nd nd [116]
↑IL-18 (serum) ↑IL-18 (serum) ↑IL-18 (serum) ↑IL-18 (serum) nd [117]
nd nd nd ↑IL-6 (mRNA) nd [124]
nd ↑IL-4, IL-18, TGFbeta, TNFalpha (mRNA)
=IL-1beta, IL-17, IL-2 (mRNA)		 nd ↑IL-4, IL-18, TGFbeta, TNFalpha (mRNA)
=IL-1beta, IL-17, IL-2 (mRNA)		 nd [125]
Neuropathic pain ref.
Peripheral NP Central NP
↑TNFalpha expression (Schwann cells) nd [132]
↑IL-2, TNFalpha (mRNA, plasma)
↓IL-4, IL-10 (mRNA, plasma)		 nd [133]
↑TNFalpha (serum) in PDN nd [134]
↑TNFalpha (plasma) in PDN nd [135]
↑IL-6 (serum) in painful DSPN nd [140]
↑TNF-alpha, IL-1beta (mRNA)
↓IL-10 (mRNA)
=IL-4 (mRNA) (in NP after peripheral nerve lesion)		 nd [16]
↑: increased concentration; ↓: decreased concentration; =: no change; Abbreviations: CM: chronic migraine, CSF: cerebrospinal fluid, DSPN: distal sensori-motor polyneuropathy, EM: episodic migraine, IL: interleukin, M0: migraine without aura, MA: migraine with aura, mRNA: messenger ribonucleic acid, NP: neuropathic pain, nd: no data available, PDN: painful diabetic neuropathy, TGF: tumor growth factor, TNF: tumor necrosis factor
Table 5. Selected human clinical data related to TRP ion channels in migraine and neuropathic pain.
Table 5. Selected human clinical data related to TRP ion channels in migraine and neuropathic pain.
Migraine ref.
EM CM
M0 MA
Ictally Interictally Ictally Interictally
nd nd nd nd ↑TRPV-1-like immunoreactive nerve fibers density in the wall of scalp arteries [150]
Neuropathic pain ref.
Peripheral NP Central NP
↓pain intensity after 8% capsaicin patch treatment
(in post-herpetic neuralgia, chronic postsurgical NP, post-traumatic NP, PDN, HIV-associated NP, painful radiculopathy, trigeminal neuralgia, chemotherapy-induced NP)		 nd [23]
[159]
[160]
[161]
↑: increased concentration; ↓: decreased concentration; =: no change; Abbreviations: CM: chronic migraine, EM: episodic migraine, HIV: human immunodeficiency virus, IL: interleukin, M0: migraine without aura, MA: migraine with aura, NP: neuropathic pain, nd: no data available, PDN: painful diabetic neuropathy, TRP: transient receptor potential
Table 6. Selected human clinical data related to endocannabinoids in migraine and neuropathic pain.
Table 6. Selected human clinical data related to endocannabinoids in migraine and neuropathic pain.
Migraine ref.
EM CM
M0 MA
Ictally Interictally Ictally Interictally
nd ↑FAAH and AMT (platelet) (only in female patients) nd nd nd [165]
nd nd nd nd ↓anandamide (CSF)
↑PEA (CSF) 		[166]
nd nd nd nd ↓AMT and FAAH (platelet) [167]
nd nd nd nd ↓anandamide and 2-AG [168]
nd =anandamide (plasma) nd =anandamide (plasma) nd [171]
Neuropathic pain ref.
Peripheral NP Central NP
nd =mean pain intensity after ultramicronized sublingually PEA treatment
(NP associated with spinal cord injury)		 [180]
↑: increased concentration; ↓: decreased concentration; =: no change; Abbreviations: 2-AG: 2-arachidonoylglycerol, AMT: anandamide membrane transporter, CM: chronic migraine, CSF: cerebrospinal fluid, EM: episodic migraine, FAAH: fatty acid amide hydrolase, M0: migraine without aura, MA: migraine with aura, NP: neuropathic pain, nd: no data available, PDN: painful diabetic neuropathy, PEA: palmitoylethanolamide
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Alerts
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2025 MDPI (Basel, Switzerland) unless otherwise stated